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Well, who are you? (Who are you? Who, who, who, who?) 
I really wanna know. (Who are you? Who, who, who, who?) 
Tell me, who you are? (Who are you? Who, who, who, who?) 
Cause I really wanna know. (Who are you? Who, who, who, who?) 
- The Who (“Who Are You”, 1978) 
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ABSTRACT 
Smooth muscle cells exist in many different locations within the body, including 
blood vessels and airways, where their principal function is contraction and 
relaxation. The heterogeneity of smooth muscle cells has been related to their 
embryological origins and could have implications in many diseases, including 
atherosclerosis, pulmonary hypertension, and asthma. Many of these diseases 
require an expandable cell source of smooth muscle cells for regenerative 
medicine or disease modeling. Here, we have developed Acta2hrGFP and 
ACTA2eGFP (GFP reporters for smooth muscle α-actin) reporter mouse and 
human induced pluripotent stem cells lines to track and isolate populations of 
smooth muscle-like cells. iPSCs were patterned to a KDR-expressing (kinase 
insert domain receptor) mesodermal progenitor, which was further specified 
towards a smooth muscle-like lineage through exposure to platelet derived 
growth factor (PDGF-BB) and transforming growth factor (TGF-β). The 
Acta2hrGFP+ or ACTA2eGFP+ cells were enriched for characteristic markers of 
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smooth muscle cells, and these cells expressed low levels of contractile markers, 
reminiscent of an immature or synthetic smooth muscle cell. Aligned smooth 
muscle-like cell sheets were generated using these iPSC-derived populations in 
an enzymatically degradable hydrogel system. The cell sheets displayed 
mechanical behavior similar to native blood vessels, with the Acta2hrGFP+ cell 
sheets displaying a higher ultimate tensile strength than Acta2hrGFP- cell sheets. 
Furthermore, we performed global transcriptomic profiling of primary adult mouse 
lung vascular (Acta2hrGFP+ Cspg4DsRed+) and airway (Acta2hrGFP+ Cspg4DsRed-) 
smooth muscle cells from a double transgenic reporter mouse, where we 
identified distinct gene signatures of lung vascular SMCs and airway SMCs, with 
Hhip and Acta2 co-expression distinguishing airway SMCs from lung vascular 
SMCs. When comparing our miPSC-derived Acta2hrGFP+ cells to these primary 
SMC signatures, the in vitro derived cells cluster closer to aortic SMCs and lung 
vascular SMCs, but their transcriptomic signatures still remain significantly 
distinct.  In addition, we have generated an Acta2hrGFP Cspg4DsRed reporter 
mouse iPSC line, which can be used to understand the signaling pathways 
involved in specification of these different smooth muscle cell subtypes. Thus, we 
have developed systems for isolating smooth muscle-like populations which have 
potential in tissue engineering applications, and we have identified gene 
signatures of adult lung vascular and airway smooth muscle cells to begin to 
address the heterogeneity of smooth muscle cell lineages.  
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CHAPTER 1: INTRODUCTION AND SPECIFIC AIMS 
 
1.1 Smooth Muscle Cells and Disease  
Smooth muscle cells are found in many different locations in the body, including 
blood vessels and airways. The main function of smooth muscle cells is to 
contract or relax, which will control the shape or tone of the tissue. Smooth 
muscle cells have been implicated in many diseases, including cardiovascular 
diseases such as atherosclerosis1-3 and pulmonary arterial hypertension4,5 as 
well as respiratory diseases such as asthma6,7. 
 
Cardiovascular disease is the leading cause of death in the United States and in 
the world8,9. Atherosclerosis is the buildup of cholesterol, fats, and cellular 
components into plaques, which lead to stenosis, or the narrowing of blood 
vessels, and reduced blood flow. Eventually, a complete blockage of the blood 
vessel may occur, resulting in a heart attack. Current treatments include lifestyle 
changes and surgical interventions such as balloon angioplasty and stenting or 
bypass grafts. The current standard for bypass grafts remains autologous grafts, 
typically the saphenous vein, internal thoracic artery, or radial artery; however, 
this process requires multiple surgeries and a suitable autologous donor graft 
might be unavailable10-13. To address the issue of graft availability, synthetic 
grafts (Gore-Tex® (expanded polytetrafluorethylene or ePTFE) and Dacron®, 
(polyethylene terephthalate or PET)) were developed using polymers; however, 
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these polymer grafts lack the ability to grow, have mechanical mismatch with the 
native blood vessel14, and often undergo stenosis and thrombosis, particularly in 
small diameter vessels.  
 
Tissue engineered vascular grafts (TEVG) attempt to address these issues by 
combining cells with biomaterials15,16 to generate blood vessel replacements that 
more similarly mimic the native blood vessel in terms of both structure and 
mechanics17,18,19. Many different strategies have been taken over the years to 
produce a viable tissue engineered graft, either using scaffold-based approaches 
or scaffold-free / self-assembly approaches. The scaffold-based engineered 
grafts utilize synthetic polymers20-22, natural polymers23-25, hybrid (synthetic and 
natural) polymers26-28, or decellularized scaffolds29-32. Polymer-based scaffold 
approaches have had success using biodegradable polymers, including 
polyglycolic acid (PGA), polylactic acid (PLA), or poly(lactide-co-glycolide) 
(PLGA), which allow for tuning of mechanical properties and degradation rate, 
but can have difficulties recapitulating native tissue structure and can require 
long periods of in vitro culture. Natural polymers, most commonly fibrin gels and 
silk, are advantageous due to their cell adhesion and biocompatibility properties, 
but they often display poor mechanical strength. Hybrid polymers attempt to 
combine the benefits of synthetic and natural polymers but may be subject to 
similar issues. In addition, many groups have attempted to mechanically 
condition these tissue engineered vascular grafts in vitro to enhance ECM 
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formation and vessel strength21,23, but these strategies increase the length of in 
vitro culture. Decellularized scaffolds utilize the natural matrix structure and 
mechanical performance of native tissue extracellular matrices; however, these 
scaffolds may induce immunogenic responses if inadequately decellularized. 
Taking an alternative approach, L’Heureaux et al. pioneered one of the earliest 
scaffold-free approaches using sheet based tissue engineering32,34, where a 
sheet of cells was wrapped around a mandrel to form a tubular vascular graft 
construct. This scaffold-free strategy has expanded, utilizing other approaches, 
such as microtissue aggregation35 and cell printing36.  
 
As we continue to work towards a clinically viable tissue engineered blood vessel 
replacement, there remain many questions and criteria to consider, including cell 
source and cell type as well as mechanical behavior. Various cell sources have 
been used, ranging from autologous differentiated cells (e.g. smooth muscle 
cells, endothelial cells, and fibroblasts)23,33, progenitor cells37, adult stem cells38, 
pluripotent stem cells39, and allogeneic or xenogenic cells21,26,27. The cell source 
will play a role in the eventual functionality of the graft as well as immunogenic 
response. In terms of mechanical behavior, the engineered construct should be 
able to: withstand the pressure of the flow of blood after implantation and match 
the compliance and mechanical behavior of the native vessel in order to prevent 
thrombosis. 
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1.2 Blood Vessel Structure and Mechanics 
The native arterial blood vessel is composed of three main layers: the tunica 
intima, the tunica media, and the tunica adventitia40. The intimal layer of blood 
vessels consists of endothelial cells which form a barrier between the blood 
vessel and the blood. The tunica media is comprised of multiple layers of 
circumferentially aligned vascular smooth muscle cells and extracellular matrix 
(ECM) proteins, specifically collagen and elastin. Each layer of vascular smooth 
muscle cells (vSMCs) is aligned in different orientations41 (Figure 1.1). The main 
function of the tunica media layer is to regulate vascular tone through 
contraction/relaxation of the vascular smooth muscle cells. The tunica adventitia 
is mostly comprised of fibroblasts, which produce collagen.  
 
Figure 1.1: Schematic of blood vessel structure. A) Schematic showing the three 
layers of the arterial wall: 1) tunica intima, 2) tunica media, and 3) tunica 
adventitia. B) Schematic showing the layer-by-layer structural organization of the 
tunica media. Each layer of smooth muscle cells and ECM proteins are oriented 
in different alignment directions. Adapted from Fox, S.I. (1993)40 and Rhodin, 
J.A.G. (1980)41. 
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The structure of the tunica media of the blood vessel plays a significant role in 
the mechanical properties of the blood vessel. The mechanical behavior of the 
blood vessel will vary on the physical and chemical environments, so mechanical 
behavior can vary greatly depending on the method of measurement and the 
blood vessel being measured42-46. When characterized using uniaxial tensile 
tests, the blood vessel exhibits an anisotropic non-linear viscoelastic response47-
49 in a passive state, where the smooth muscle cells are inactive (Figure 1.2). 
The passive mechanical behavior of the arterial wall is determined by the 
quantity and ratio of collagen and elastin fibers50-53. When the smooth muscle 
cells are in an active contractile state, the mechanical behavior becomes more 
complex and changes drastically49,54. Furthermore, the different layers of the 
blood vessels display different mechanical properties55. 
 
 
Figure 1.2: Schematic showing stress-strain response of an arterial wall. Adapted 
from Holzapfel et al. (2000)47. 
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1.3 Smooth Muscle Cell Phenotype, Diversity, and Development 
The main function of smooth muscle cells is to contract and control the tone and 
shape of a blood vessel; however, many studies have shown, particularly in 
vascular smooth muscle cell populations, that smooth muscle cells are extremely 
plastic and undergo “de-differentiation” to a synthetic phenotype during injury and 
repair56-59.  The changes in this phenotype happen in response to local 
environmental cues including growth factors, mechanical cues, and cell-cell cell-
matrix interactions (Figure 1.3A). This diversity in smooth muscle cell phenotype 
along the spectrum of synthetic to contractile phenotype can be characterized 
both morphologically as well as through protein markers, including ACTA2 (α-
SMA), MYH11 (SM-MHC), and SMTN (smoothelin) (Figure 1.3B). A limitation of 
these markers is that these markers do not exclusively mark smooth muscle 
cells, making it difficult to use these markers as “lineage markers” or 
“differentiation / phenotype markers”. ACTA2, one of the most widely used 
characteristic markers of smooth muscle cells, is the earliest known protein 
expressed in smooth muscle cells during development60, 61, but it is also widely 
expressed in skeletal and cardiac muscle during development62, in adult 
cardiomyocytes63, and in myofibroblasts64. TAGLN, or SM22α, also exhibits a 
similarly wide expression pattern to ACTA265-67. SMTN has been shown to be 
expressed in two different isoforms found in either vascular or visceral smooth 
muscle cells68,69, but it is also expressed at high levels in other tissues. MYH11 
seems to be specific to smooth muscle cells in vivo; however, there are some 
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reports indicating expression of MYH11 outside of smooth muscle cells70,71. The 
transcription of these smooth muscle cell genes is regulated by interactions 
between serum response factor (SRF) and CArG elements, which is regulated by 
a transcriptional co-regulator, MYOCD (myocardin)72-74. MYOCD is expressed 
specifically in smooth muscle cells and cardiac muscle cells, although more 
tissue specific splice variants have been described181. Furthermore, there are two 
myocardin-related transcription factors (MRTF-A and MRTF-B) that are more 
widely expressed than myocardin but are strongly expressed in SMCs. MRTF-A 
and MRTF-B deficient mouse studies have affected different cell types, indicating 
that the MRTFs have unique roles in the expression of SMC markers and 
development182-183. 
 
Environmental factors that affect the phenotype of smooth muscle cells includes 
growth factors76-78, mechanical forces79,80, contractile agonist81-83, extracellular 
matrix components84-86, reactive oxygen species87, and endothelial-SMC 
interactions88. Biochemical factors that modulate smooth muscle phenotype 
include PDGF-BB and TGF-β, with PDGF-BB generally inducing a more 
synthetic phenotype and TGF-β inducing a more contractile phenotype. However, 
the effect and role of TGF-β is still controversial, with TGF-β inducing a wide 
range of responses. Many other biochemical factors, including activin A, FGFs, 
and retinoids, also influence the phenotypic differentiation of smooth muscle 
cells. Retinoic acid treatment increases expression of smooth muscle markers89 
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and decreases proliferation90. Extracellular matrix (ECM) proteins mediate 
phenotype changes through binding to specific integrin receptors91. This 
relationship between ECM proteins and SMC phenotype can be complex. 
Collagen type I has been shown to promote contractile phenotypes when in a 
fibrillar form and induces a more synthetic phenotype when in a monomeric 
form92. Physical cues, such as micropatterned surfaces75, have also been shown 
to induce changes in the smooth muscle cell phenotype based on gene 
expression level of markers. 
 
Although heterogeneity of smooth muscle cells regarding synthetic and 
contractile phenotype have been well studied, there has been significantly less 
research on heterogeneity of smooth muscle cells from different anatomical 
locations. More recently, the developmental basis for vascular smooth muscle 
heterogeneity and its role in vascular disease has begun to be explored in 
detail93-101. Smooth muscle cells have been shown to derive from both neural 
crest and mesodermal origins (Figure 1.4). Depending on the developmental 
origin of the smooth muscle cell, the structure and physiology of the blood vessel 
will differ102, and the smooth muscle cells will have different levels of expression 
of MMP996 and NOTCH3103. 
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Figure 1.3: Schematic representation of synthetic and contractile phenotypes of 
smooth muscle cells. A) Schematic of extrinsic factors and local environmental 
cues that influence differentiation / de-differentiation between synthetic and 
contractile phenotypes. B) Schematic representation of expression level of genes 
associated with synthetic and contractile phenotypes. Adapted from Owens et al. 
(2004)56 and Rensen et al (2007)58. 
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Furthermore, the differences between vascular smooth muscle cells and other 
smooth muscle cell types have been characterized even less. Smtn, as 
mentioned earlier, is expressed as two different isoforms, which are found in 
either vascular or visceral smooth muscle cell populations. NOTCH3103,104 and 
Cspg4105 have also been previously described as being able to distinguish 
between vascular and airway smooth muscle cells in human iPSC and mouse 
model systems, respectively. Furthermore, the co-expression of Cspg4 with 
Acta2 is restricted to arteries and arterioles and not veins106,107. A global 
transcriptional profiling of cultured and propagated human smooth muscle cells 
from different anatomical locations112 revealed differences in gene signatures; 
however, no fresh primary SMC gene signatures of different smooth muscle 
subtypes have been described. As research continues to reveal differences in 
disease pathology between smooth muscle cells from different embryological 
origins, we will need better signatures to identify the different smooth muscle 
subtypes. 
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Figure 1.4: Schematic showing embryological origins of smooth muscle cells 
from different anatomical locations97.  
 
1.4 Pluripotent Stem Cells 
Pluripotent stem cells are stem cells that have the capability to self-renew 
indefinitely and differentiate into all three germ layers of the embryo but not the 
extraembryonic tissues118,119. There are two types of pluripotent stem cells: 
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). 
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Embryonic stem cells are derived from the inner cell mass of the developing 
blastocyst113-116, and the characteristics of that developmental stage, including 
the ability to differentiate into all three germ layers117, were maintained in vitro. 
The discovery of induced pluripotent stem cells (iPSCs) through the 
overexpression of four transcription factors allows for reprogramming of somatic 
cells to a pluripotent state118-123. iPSCs have been shown to be functionally 
similar to ESCs in that they self-renew indefinitely and have the ability to 
differentiate into all three germ layers118,119,123. The ability to generate iPSCs from 
any person enhances the potential of pluripotent stem cell research as it allows 
for patient-specific iPSC lines, which provide an inexhaustible source of patient-
derived cells for cell-based therapy and tissue engineering applications as well 
as for disease modeling (Figure 1.5).  
 
Reprogramming of somatic cells is induced through overexpression of four 
pluripotency transcription factors: Oct4, Klf4, Sox2, and c-Myc (OKSM)118,119. 
Many methods have been developed to introduce the OKSM factors into 
differentiated cells for reprogramming. One such method involves using a 
lentiviral “stem cell cassette” (STEMCCA) that integrates into the genome to 
overexpress the OKSM factors, which can then be excised using site-specific 
recombinases (e.g. Cre) that recognize specific sequences (e.g. Lox) 
surrounding this cassette124-127. The removal of the overexpression of OKSM 
factors in the STEMCCA system augments the differentiation potential of the 
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reprogrammed cells126. Other methods include using Sendai virus128, an 
integration-free viral method of reprogramming, DNA plasmid-based 
approaches129-131, and mRNA or protein-based reprogramming132-134. 
Furthermore, addition of other biochemical factors, such as valproic acid135 or 
ascorbic acid136, as well as mechanical cues137 have been utilized to enhance 
reprogramming efficiency.   
 
Figure 1.5: Schematic illustrating the potential of induced pluripotent stem cells. 
iPSCs can be derived from various differentiated cell types through viral plasmid, 
or mRNA induction of overexpression of four key transcription factors: Oct4, Klf4, 
Sox2, c-Myc. iPSCs can be gene edited using CRISPR, TALEN or ZINC finger 
strategies to correct gene mutations, knock out genes or insert transgenes. 
Furthermore, iPSCs can be differentiated into all three germ layers to various cell 
types of interest for drug screening, cell therapy, or disease modeling 
applications. Adapted from Diecke et al. (2014)138. 
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1.5 Directed Differentiation of Pluripotent Stem Cells 
Since the development of pluripotent stem cells, directed differentiation of PSCs 
towards diverse cell types of interest has been a major research focus. Many 
directed differentiation approaches follow our understanding of development and 
pushes the PSCs through different sequential stages using signaling pathways 
that occur during development. The stage-specific directed differentiation of 
PSCs allows for interrogation of cell fate decisions, but it also generates patient-
specific cells for tissue engineering applications as well as disease modeling. 
 
Various pluripotent stem cell directed differentiation protocols towards a smooth 
muscle lineage have been published in literature139-142. Both serum-containing 
differentiation protocols143-147 and serum-free differentiation protocols95,96,148,149 
have been published. Meanwhile, some protocols rely on overexpression of 
regulators of smooth muscle gene expression, such as myocardin. Yoshida et al. 
demonstrated that forced overexpression of myocardin in multiple cell lines, 
including an embryonal A404 smooth muscle precursor cells and mouse 
embryonic stem cells, increased gene expression of some smooth muscle 
markers, such as smooth muscle actin and smooth muscle myosin heavy chain, 
which are CArG-dependent151. However, a subset of smooth muscle markers, 
such as smoothelin B and aortic carboxypeptidase-like protein (AEBP1), which 
are CArG-independent. Raphel et al. described an embryoid body method for 
human embryonic stem cells that were cultured with serum and transduced with 
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adenoviruses expressing myocardin152. The resulting smooth muscle-like cells 
had increased expression of smooth muscle actin, calponin and smooth muscle 
myosin heavy chain, but also without increased expression of CArG-independent 
smooth muscle marker genes. The SM-like cells also displayed increased 
contractility with myocardin overexpression. While both of these studies 
demonstrated increased gene expression and contractility, there remains a 
subset of smooth muscle marker genes, which are CArG-independent, that are 
not expressed. Furthermore, the populations of cells were heterogeneous, with 
the SM-like cells only making up a subset of the population. Ji et al. also utilized 
a myocardin lentiviral transducible overexpression system to induce endothelial 
progenitor cell transdifferentiation to smooth muscle cells153 based off of smooth 
muscle marker gene expression of ACTA2, TAGLN, and MYH11. This study 
demonstrated the use of myocardin overexpression to induce a smooth muscle-
like phenotype from an expandable patient-specific source; however, the effect of 
lentiviral integration could influence downstream clinical applications and the 
population of cells still remains heterogeneous. In addition, this study did not 
interrogate cardiac marker gene expression since cardiac marker gene 
expression was not upregulated in a non-muscle cell line73 despite myocardin 
being a transcriptional regulator of both smooth muscle and cardiac marker gene 
expression. 
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Since smooth muscle cells are derived from multiple embryological lineages, 
such as neural crest and mesodermal lineages, some groups have taken stage-
specific approaches to pattern the pluripotent stem cells towards neural crest, 
paraxial mesoderm, or lateral plate mesoderm before further specifying the cells 
towards a smooth muscle cell lineage using serum-containing1146 or serum-free 
media95,96. Wang et al. used iPSC-derived neural crest cells to generate a 
smooth muscle-lineage through treatment with serum and TGF-β146. Although 
these cells expressed smooth muscle actin, transgelin, calponin, and smooth 
muscle myosin heavy chain by staining, more detailed characterization was not 
performed. The Sinha group has described serum-free differentiation protocols of 
PSCs to smooth muscle-like cells through neuroectoderm, lateral plate 
mesoderm, and paraxial mesoderm intermediates95,96,103,154. They characterized 
these cells using expression of characteristic smooth muscle markers and global 
gene expression profiling compared to human ESCs; however, they lack global 
profiling compared to fresh primary SMC controls. Furthermore, although Cheung 
et al. described differences in MMP and TIMP expression between SMCs from 
different intermediate lineages, the final population of cells, which was profiled, 
was not 100% smooth muscle cells. These studies begin to probe the differences 
between embryological origins in the final iPSC-derived smooth muscle 
phenotype; however, a method to isolate pure populations of SMCs and global 
profiling compared to primary smooth muscle cell controls are still necessary. In 
addition, the study only compares the iPSC-derivatives to vascular SMCs, but 
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airway SMCs are also derived from lateral plate mesoderm, so it will be important 
to identify what type of SMC is being derived in these directed differentiation 
protocols. Other groups have patterned the cells to a KDR-expressing (kinase 
insert domain receptor) mesodermal intermediate, which has shown to have 
competence to be further specified to multiple lineages155-159. Cheung et al. also 
described their lateral plate mesoderm to have KDR expression. Patsch et al. 
also describes using Wnt and BMP pathway induction to pattern PSCs through a 
mesodermal progenitor to a smooth muscle-like cell160. Although they describe a 
high percentage yield of smooth muscle cells, the population was not 
homogenous. These stage specific approaches follow developmental pathways 
that play a role in smooth muscle cell development in vivo, which will be 
important in deriving specific smooth muscle cell subtypes.  
 
Although some differentiation protocols utilize a selection / purification 
process145, a majority of protocols only characterize their smooth muscle 
populations through staining, flow cytometry, and gene expression of some 
characteristic smooth muscle cell markers; however, these markers, as 
described in Section 1.3, are not only expressed in smooth muscle cells. Some of 
these studies have also performed functional characterizations, showing 
response of cells to contractile agonist96,152,160. Some of these studies have even 
incorporated these cells into tissue-engineered constructs39,147. However, more 
detailed characterization of pure populations of smooth muscle-like cells from the 
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directed differentiation is still necessary to ensure that these iPSC-derived 
populations are smooth muscle cells and to determine what smooth muscle cell 
subtype (e.g. vascular SMC or airway SMC) is being derived. Isolation of pure 
populations would also be necessary for downstream tissue engineering 
applications, disease modeling, and drug screening. 
 
1.6 Cell Sheet Engineering 
Current solutions for tissue engineered blood vessel replacements often 
incorporate cells with biomaterials, such as polymers or decellularized tissue15,16. 
Although these approaches allow for tuning of mechanical properties, 
degradation rates of polymers, or maintenance of extracellular matrix protein 
structure, these biomaterials are often subject to mechanical mismatch or can 
induce an immunogenic response. Furthermore, some scaffolds are unable to 
grow with the patient following implantation which can affect the long-term 
patency of the graft if implanted into children.  
 
Cell sheet engineering was developed to provide a system to generate a layer-
by-layer approach to recapitulate tissue structure without the presence of 
scaffolds or biomaterial. One of the most commonly used materials for cell sheet 
engineering strategies is poly(N-isopropylacrylamide) (pNIPAAm), a thermos-
responsive polymer161-163. pNIPAAm has a lower critical solution temperature 
(LCST) of 32°C, where the polymer switches conformation between a 
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hydrophobic state, allowing for cell attachment, and a hydrophilic state, allowing 
for non-damaging cell detachment and maintenance of cell-cell junctions and 
cell-ECM interactions. Temperature-responsive surfaces were initially made 
using a high-energy electron beam to graft pNIPAAm onto the surface of tissue-
culture treated polystyrene dishes161. An inexpensive approach utilized soft 
lifthography techniques to make a micropatterned poly(dimethylsiloxane) (PDMS) 
substrate grafted with pNIPAAm for the generation of aligned cell sheets162,163. 
Multiple groups have demonstrated the ability to stack these cell sheets in a 
layer-by-layer manner. Other groups have developed strategies to generate cell 
sheets using different thermo-responsive polymers164, magnetic-based 
systems165,166, and electro-responsive systems167. Our group has recently utilized 
a tyramine-conjugated carboxymethylcellulose (CMC)-based and alginate (Al)-
based hydrogel system to fabricate cell sheets, which can be released through 
hydrogel-specific enzymatic degradation168-169.  Soft lithography techniques can 
be utilized with this system to micropattern the hydrogel surfaces and induce 
alignment of cells. Furthermore, the stiffness of CMC and Al hydrogels can be 
modulated to study the effect of biomechanical cues on cell phenotypes. 
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Figure 1.6: Cell sheet engineering technologies. A) Temperature responsive 
system using poly(N-isopropylacrylamide) (pNIPAAm). B) Temperature 
responsive hydrogels using Tetronic-tyramine. C) Magnetic system where cells 
are labeled with magnetite nanoparticles. Electroresponsive system through 
exposure or concealment of RGD peptides under different electric potentials. 
Adapted from Akintewe et al (2017)170. 
 
1.7 Hypothesis and Specific Aims 
The overall goal of this dissertation project is 1) to develop mouse and human 
induced pluripotent stem cell-based reporter systems to generate pure 
populations of smooth muscle-like cells for cell sheet engineering applications 
and 2) to identify molecular gene signatures of primary SMC subtypes, 
specifically lung vascular SMCs, airway SMCs, and aortic SMCs, in order to 
better understand and characterize SMC phenotype in iPSC directed 
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differentiations. Based on previous literature on the development of SMCs and 
the in vitro directed differentiation of SMCs, the hypothesis of this project is that 
an Acta2 reporter will allow for enrichment of smooth muscle-like cells, which can 
be used to form cell sheets with mechanical behavior similar to that of native 
blood vessels Furthermore, the identification of molecular gene signatures of 
primary SMCs will better inform directed differentiation protocols towards SMC 
subtypes. The goals of this project were accomplished through four specific aims: 
 
Aim 1: Generate smooth muscle-like populations from a mouse Acta2hrGFP 
induced pluripotent stem cell line 
 Generate a transgenic Acta2 mouse reporter induced pluripotent stem cell 
line for generation and isolation of smooth muscle-like cells 
 Derive and characterize miPSC-derived Acta2hrGFP+ populations 
 
Aim 2: Engineer an ACTA2eGFP human reporter induced pluripotent stem 
cell system for generating smooth muscle-like lineages 
 Generate a knock-in ACTA2 human reporter induced pluripotent stem cell 
line for tracking and purification of smooth muscle-like cells  
 Derive and characterize hiPSC-derived ACTA2eGFP+ populations 
 
Aim 3: Generate functional iPSC-derived cell sheets as building blocks for 
smooth muscle cell sheet engineering applications  
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 Generate cell sheets from Acta2hrGFP and ACTA2eGFP populations from  
mouse and human induced pluripotent stem cell reporter lines 
 Characterize the mechanical properties / behavior and extracellular matrix 
content of iPSC-derived cell sheets 
 
Aim 4: Identify gene signatures of primary SMC subtypes, including lung 
vascular SMCs, airway SMCs, and aortic SMCs, against which to compare 
iPSC-derived smooth muscle-like lineages 
 Identify gene signatures of primary smooth muscle cell subtypes using 
microarray profiling 
 Generate a double transgenic Acta2hrGFP Cspg4DsRed reporter mouse 
induced pluripotent stem cell line for tracking and purification of SMC 
subtypes 
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CHAPTER 2: GENERATION OF A MOUSE Acta2hrGFP REPORTER iPSC 
SYSTEM FOR DERIVATION AND ISOLATION OF SMOOTH MUSCLE-LIKE 
CELLS 
 
2.1 Introduction 
Current protocols for differentiation of pluripotent stem cells towards a smooth 
muscle lineage have various limitations. Many protocols utilize serum-based 
media, which are not well defined and can lead to batch to batch variations and 
experimental variability. Other protocols use a serum-free defined media; 
however, the protocols are not 100% efficient for smooth muscle cell derivation. 
We therefore generated a reporter mouse induced pluripotent stem cell line to 
track, purify, and characterize cells during directed differentiation towards a 
smooth muscle lineage using a defined serum-free media. Acta2 is one of the 
earliest characteristic markers of smooth muscle cells expressed during 
development; however, Acta2 is an intracellular marker, which makes it difficult 
for tracking Acta2 expression in live cells. Since Acta2 is one of the earliest 
markers of smooth muscle cells, we chose this gene as the readout for our 
reporter and sought to develop an Acta2 promoter-driven GFP reporter. 
 
Smooth muscle cells derive from different embryological origins, including lateral 
plate mesoderm, paraxial mesoderm, and neuroectoderm97. Coronary artery 
vascular SMCs, aortic root SMCs, and lung vascular and airway SMCs, derive 
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from the lateral plate mesoderm. Kdr+ mesodermal progenitor has been shown 
to be competent to differentiate into many lineages including smooth muscle 
cells.  
 
In this study, we generated an Acta2hrGFP mouse induced pluripotent stem cell 
system to track and isolate Acta2hrGFP+ smooth muscle-like cells. The work 
presented in this chapter indicates that we can derive Acta2+ cells through a 
mesodermal progenitor towards a smooth muscle-like lineage, following 
developmental cues in in vivo developmental models. Our findings also show that 
the Acta2hrGFP+ cells have transcriptomic profile that is reminiscent of 
immature/synthetic smooth muscle cells. This reporter miPSC system will allow 
for tracking and purification of putative smooth muscle-like cells for tissue 
engineering applications and can also be used to further interrogate pathways 
involved in smooth muscle cell specification and maturation. 
 
2.2 Methods 
Generation of Acta2hrGFP Mouse iPSC Reporter System for Isolation of 
Smooth Muscle-like Cells 
An Acta2hrGFP reporter mouse iPSC line was generated using methods as 
previously described in literature104. In brief, tail tip fibroblasts (TTFs) were 
isolated from adult C57BL/6 Acta2hrGFP transgenic mice104 and expanded in 
media containing DMEM, 10% FBS, L-glutamine, and Penicillin Streptomycin. 
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After 3 passages, TTFs were infected with a single Cre-excisable lentiviral vector 
(STEMCCA-loxP), which encodes for the 4 reprogramming transcription factors: 
Oct4, Klf4, Sox2, and cMyc124-127. During reprogramming, mouse iPSC lines were 
grown in mouse ESC media supplemented with either recombinant LIF or 
conditioned LIF media (DMEM supplemented with 15% FBS, L-glutamine, BME, 
LIF, and primocin as previously described175). Mouse iPSC lines were 
mechanically isolated between 15-20 days post-infection with STEMCCA-loxP 
and expanded on an inactivated feeder layer of mouse embryonic fibroblasts 
(MEFs) to establish clonal miPSC lines. After clonal expansion, the STEMCCA 
cassette was excised using an adenoviral vector expressing Cre-recombinase 
(Adeno-Cre). Excised lines were stained with pluripotency markers Oct4, Nanog, 
and alkaline phosphatase using standard techniques. Excised clones were 
screened for Cre-excision of STEMCCA cassette, and a karyotypically (Cell Line 
Genetics, Madison, WI) normal female mouse iPSC line was used for all directed 
differentiation experiments. Mouse iPSC lines were further maintained on MEFs 
in mESC media for all experiments.  
 
Directed Differentiation of Mouse PSCs Towards Acta2hrGFP+ Population of 
Smooth Muscle-Like Cells 
Mouse iPSCs were differentiated through a mesodermal progenitor expressing 
Kdr and then further specified towards a smooth muscle-like lineage using 
previously reported methods155,156. Briefly, embryoid bodies (EBs) were formed 
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during 48 hours of LIF withdrawal in a complete serum-free differentiation 
medium (cSFDM – IMDM, Ham’s F12, Glutamax, B27, N2, BSA, MTG, ascorbic 
acid, and Primocin)155,156. EBs were then treated with 2 ng/mL activin A (R&D 
Systems), 3 ng/mL BMP4 (R&D Systems), and 3 ng/mL Wnt3a (R&D Systems) 
for 72 hours to generate Kdr+ mesodermal progenitors. Kdr+ EBs were then 
plated onto gelatin coated plates in cSFDM supplemented with 10 ng/mL of 
PDGF-BB (Invitrogen) and 10 ng/mL of mouse TGF-β (R&D Systems). Cells 
were dissociated and flow sorted using a FACSAria or MoFlo Legacy (Beckman 
Coulter, Brea, CA) at the Boston University Medical Center Flow Cytometry Core 
based on GFP expression for analysis on day 13.  
 
Microarray Profiling of Mouse iPSC-Derived Acta2hrGFP+ and Acta2hrGFP- 
Populations 
RNA was extracted using a QIAzol Lysis Reagent (Qiagen, Venlo, Netherlands) 
for the following samples: undifferentiated miPSCs (day 0), sorted Kdr+ 
mesodermal progenitors from day 5 of differentiation, purified Acta2hrGFP+ and 
Acta2hrGFP- populations from day 13 of differentiation, and primary Acta2hrGFP+ 
cells from adult mouse aortas. Each RNA sample for adult mouse aorta was RNA 
extracted from pooled aortas of three adult mice. The samples from the 5 
different conditions were profiled using the Affymetrix® Mouse Gene 2.0 ST 
Array platform at the Boston University Microarray Core. The Mouse Gene 2.0 
ST CEL files were normalized to produce gene-level expression values using the 
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implementation of the Robust Multiarray Average (RMA)195 in the affy package 
(version 1.36.1)196 included in the Bioconductor software suite (version 2.12)197 
and an Entrez Gene-specific probeset mapping (17.0.0) from the Molecular and 
Behavioral Neuroscience Institute (Brainarray) at the University of Michigan198,199. 
Array quality was assessed by computing Relative Log Expression (RLE) and 
Normalized Unscaled Standard Error (NUSE) using the affyPLM package 
(version 1.34.0)200. Principal Component Analysis (PCA) was performed using 
the prcomp R function with expression values that had been normalized across 
all samples to a mean of zero and a standard deviation of one. Differential 
expression was assessed using the moderated (empirical Bayesian) ANOVA and 
t test implemented in the limma package (version 3.14.4) (i.e., creating simple 
linear models with lmFit, followed by empirical Bayesian adjustment with 
eBayes). Correction for multiple hypothesis testing was accomplished using the 
Benjamini-Hochberg false discovery rate (FDR)201. Human homologs of mouse 
genes were identified using HomoloGene (version 68)202. All microarray analyses 
were performed using the R environment for statistical computing (version 
2.15.1). 
 
Gene Set Enrichment Analysis 
Gene set enrichment analysis was performed on the microarray dataset203,204. 
Briefly, GSEA was performed using MSigDB v5.2 hallmark gene sets 
(http://software.broadinstitute.org/gsea/index.jsp) on our microarray database 
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comparing the different stages of our miPSC directed differentiation protocol with 
primary aortic SMCs. The genes were ranked according to the t statistic 
computed between the populations being compared, and the ranked list was 
used to perform pre-ranked GSEA analyses. Significant pathways were 
considered those with Benjamini-Hochberg false discovery rate FDR q-value < 
0.1. 
 
Reverse Transcriptase Quantitative Real Time Polymerase Chain Reaction 
(RT-qPCR) 
Quantification of mRNA expression was performed using reverse transcriptase 
quantitative real time polymerase chain reaction (RT-qPCR) as previously 
described. RNA was extracted from cells using QIAzol Lysis Reagent (Qiagen, 
Venlo, Netherlands) or using a RNeasy Plus Mini Kit (Qiagen, Venlo, 
Netherlands). cDNA was generated using reverse transcription reagents (Applied 
Biosystems) from 150 ng of RNA. qPCR was performed using TaqMan Fast 
Universal PCR Master Mix (ThermoFisher) and Taqman (Applied Biosystems) 
probes. cDNA was then diluted 1:3 and 2 μL of cDNA was used in a 25 μL qPCR 
reaction (Applied Biosystems StepOne 96-well System) or in a 12.5 μL qPCR 
reaction (Applied Biosystems QuantStudio7 384-well System). Samples were run 
in biological triplicates, each with technical triplicates, and threshold cycle (Ct) 
values were averaged between technical triplicates for analysis. Relative mRNA 
gene expression was normalized to an 18S control, and then calculated as fold 
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change in gene expression relative to a baseline control sample, using a 2-ΔΔCt 
method174,192. The baseline, fold change of 1, was set to undifferentiated iPSC 
mRNA expression levels. Undetected Ct values were set to a value of 40 for 
calculating fold changes. 
 
Statistical Methods 
Unpaired, two-tailed Student’s t-tests were used to compare quantitative 
analyses comprising two groups of n=3 or more samples, where each replicate 
represents either separate differentiation runs from the pluripotent stem cell 
stage or replicates from the same differentiation plated into different wells. The p-
value threshold to determine significance was p<0.05. Data is represented as the 
mean with the error bar representing the standard deviation of the mean.  
 
2.3 Results 
Generation of Mouse iPSC-Derived Acta2hrGFP+ Cells 
In order to identify and purify a population of smooth muscle-like cells, we 
generated mouse iPSCs from the tail tip fibroblasts of a transgenic mouse that 
expresses humanized Renilla reniformis green fluorescent protein (hrGFP) 
following a rat Acta2 promoter sequence (Acta2hrGFP) (Figure 2.1A)104. Mouse 
iPSCs were reprogrammed using STEMCCA, a lentiviral cassette that integrates 
and overexpresses Oct4, Sox2, Klf4, and c-Myc124-127. Following Cre-excision of 
the STEMCCA cassette, a single clonal miPSC line was characterized for 
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pluripotency markers and was karyotypically normal (Figure 2.1B and C).  
 
 
Figure 2.1: Generation of Acta2hrGFP reporter mouse iPSC line for isolation of 
Acta2-expressing populations.  A) Schematic of Acta2hrGFP mouse iPSC line 
generation and differentiation towards a smooth muscle-like population. B) 
Alkaline phosphatase staining of Acta2hrGFP miPSC line, and C) karyotype of 
Acta2hrGFP miPSC line. 
 
 
Figure 2.2: Schematic of mouse induced pluripotent stem cell directed 
differentiation protocol towards smooth muscle-like cells. 
 
To differentiate the Acta2hrGFP miPSC line towards a smooth muscle lineage, we 
took a stage-specific approach to pattern the cells towards a Kdr+ mesodermal 
progenitor, which could then be specified towards a smooth muscle lineage using 
PDGF and TGF-β signaling (Figure 2.2).  As described previously in the 
literature, BMP, Nodal, and Wnt signaling are important during gastrulation and 
patterning of the primitive streak, with BMP signaling being important for 
posteriorizing the primitive streak towards the mesodermal germ layer155,156. We 
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developed methodologies for optimizing the mesoderm induction in our cell line 
by testing doses of BMP4, Activin A, and Wnt3a as well as duration of mesoderm 
induction. To optimize the dose of BMP4 Activin A, and Wnt3a during mesoderm 
induction, we utilized a TGFP Foxa2hCD4 mouse ESC (mESC) line194, where a GFP 
reporter and human CD4 cDNA sequence were knocked-in to the Brachyury (T) 
and Foxa2 loci, respectively (This line was a generous gift from the Gordon 
Keller laboratory at Mt Sinai School of Medicine). Using this mESC line, we can 
track the patterning of the PSCs during differentiation towards the primitive 
streak. T, or brachyury, is a marker of primitive streak formation, and Foxa2 is 
expressed in the anterior region of the primitive streak, the site of endoderm 
induction. Therefore, during development, endoderm lineages are characterized 
by high Foxa2 expression, while mesoderm is characterized by low or negative 
Foxa2 expression. We tested various doses of BMP4 and Wnt3a while holding 
the concentration of Activin A at 2 ng/mL (Figure 2.3). Without BMP4 or Wnt3a, 
the mESCs did not undergo patterning towards the primitive streak as shown by 
the lack of Brachyury expression. With exposure to either BMP4 or Wnt3a, we 
observed patterning of mESCs towards primitive streak (Figure 2.3A). Low 
concentrations of BMP4 (0 ng/mL and 0.3 ng/mL) induced TGFP+ Foxa2hCD4hi 
populations. As we continued to increase BMP4 concentration (3 ng//mL and 10 
ng/mL), mESCs were patterned towards a posterior primitive streak, 
characterized by TGFP+ Foxa2hCD4low populations. The posteriorizing conditions (3 
ng/mL and 10 ng/mL of BMP4) contained a population of Kdr+ cells with 3 ng/mL 
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of BMP4 and 3 ng/mL of Wnt3a yielding the highest percent of Kdr+ cells.  
 
Figure 2.3: Flow cytometry plots showing mesodermal marker expression in TGFP 
Foxa2hCD4 mouse embryonic stem cells in response to doses of BMP4 and 
Wnt3a. All conditions contain 2 ng/mL of Activin A. A) Flow cytometry plots of 
TGFP and Foxa2hCD4 expression. B) Flow cytometry plots of TGFP and Kdr 
expression. 
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After optimizing the dosing of BMP4, Wnt3a, and Activin A in the TGFP Foxa2hCD4 
mESC line, we differentiated the Acta2hrGFP mouse iPSC line towards Kdr+ 
mesodermal progenitors. We assessed the percentage of Kdr+ cells over the first 
6 days of the directed differentiation to establish a kinetic of Kdr expression. The 
percentage of Kdr+ cells peaked on day 5 with an average of ~25% Kdr+ cells 
(Figure 2.4A). As described in the literature, the early mesodermal germ layer 
can be further sub-classified into lateral plate mesoderm, paraxial mesoderm, 
and intermediate mesoderm184. SMCs from different anatomical regions have 
been shown to derive from these different mesodermal layers, so we wanted to 
characterize our Kdr+ mesodermal progenitor population in our directed 
differentiation to better understand what developmental stages our cells are 
going through. The Kdr+ population was enriched for Kdr as well as Foxf1, a 
lateral plate mesoderm marker (Figure 2.4B). Meanwhile, Pax2 (intermediate 
mesoderm) and Tbx6 (paraxial mesoderm), were lowly expressed in the Kdr+ 
population.  Both the Kdr+ and Kdr- populations expressed high levels of T and 
low levels of Foxa2, and at this early stage do not express the smooth muscle 
marker, Acta2. 
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Figure 2.4: Characterization of Kdr mesodermal intermediate during mouse iPSC 
directed differentiation. A) Kinetic of KDR expression during directed 
differentiation. B) Gene expression of mesodermal markers in Kdr+ and Kdr- 
populations. RT-qPCR measurements of fold change (2-ΔΔCt) of mRNA 
expression is shown for Kdr+ and Kdr- populations. Undifferentiated miPSC 
mRNA expression is defined as fold change = 1. Bars represent ± S.D. * p≤0.05 
and ** p≤0.01 by unpaired two-tailed Student’s t-test between Kdr+ and Kdr- 
populations. 
 
Next, to understand the competence of the mesodermal precursors to 
differentiate towards a smooth muscle-like cell, we sorted Kdr+ and Kdr- 
populations on day 5 and re-plated these cells in differentiation media containing 
PDGF-BB, TGF-β, and FGF2 or 10% serum. The percent Acta2hrGFP+ cells was 
significantly enriched in the outgrowth of Kdr+ replated population as compared 
to that of the Kdr- population (Figure 2.5), indicating that the Kdr+ population 
contains the majority of cells competent to differentiate to Acta2hrGFP+ cells. By 
day 13, an Acta2hrGFP+ population of ~26% arises (Figure 2.6A) on average. The 
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Acta2hrGFP+ cells showed enriched gene expression of characteristic smooth 
muscle markers, such as Acta2, Tagln, Myh10, Col1a1, Eln, and Myh11. The 
early / synthetic smooth muscle markers (Acta2, Col1a1, and Eln) were more 
highly expressed, while the mature/ contractile smooth muscle marker (Myh11) 
was enriched but lowly expressed. Meanwhile, the Acta2hrGFP+ population was 
depleted for markers of endothelial cells (VE-cad), podocytes (Podxl), and 
epithelial cells (Cdh1) (Figure 2.6B). Staining for Acta2 in the iPSC differentiation 
revealed that all Acta2hrGFP+ cells expressed Acta2; however, there are Acta2+ 
cells that were not marked by the hrGFP reporter (Figure 2.6C). Since Acta2 has 
also been shown to be expressed in cardiomyocytes, we wanted to quantify the 
presence of cardiomyocytes in our directed differentiation. We performed flow 
cytometry on day 13 cells intracellularly stained for Troponin T Type 2 (Tnnt2), a 
marker of cardiomyocytes. About 1% of Acta2hrGFP+ cells were Tnnt2+ using our 
defined serum-free differentiation media condition of PDGF-BB, TGF-β, and 
FGF2, while 3% of Acta2hrGFP+ cells were Tnnt2+ using a serum based 
differentiation media (Figure 2.7). There was a corresponding increase in Tnnt2 
gene expression in the whole day 13 cell population.  
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Figure 2.5: Competence of Kdr+ and Kdr- populations to differentiate to an 
Acta2hrGFP+ population. Bars represent ± S.D. ** p≤0.01 and **** p≤0.0001 by 
unpaired two-tailed Student’s t-test between Kdr+ and Kdr- populations. 
 
 
Figure 2.6: Characterization of Acta2hrGFP populations on day 13 of miPSC 
directed differentiation.  A) Flow cytometry plot of Acta2hrGFP and Kdr expression. 
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B) Gene expression of characteristic smooth muscle cell markers as well as 
markers of endothelial cells, podocytes, and epithelial cells. RT-qPCR 
measurements of fold change (2-ΔΔCt) of mRNA expression is shown for presort, 
GFP+, and GFP- populations. Undifferentiated miPSC mRNA expression is 
defined as fold change = 1. Bars represent ± S.D. * p≤0.05, ** p≤0.01, *** 
p≤0.001, **** p≤0.0001by unpaired two-tailed Student’s t-test between GFP+ and 
GFP- populations. C) Immunofluorescence images of hrGFP (green), Acta2 
(red), and nuclei (blue).  
 
 
Figure 2.7: Troponin T Type 2 (Tnnt2) protein and gene expression on day 13 of 
miPSC directed differentiation. 
 
Global transcriptomic analysis of directed differentiation of mouse PSCs 
To characterize the global gene expression kinetics of the mouse iPSC-derived 
Acta2hrGFP+ cells during the directed differentiation process in comparison to 
primary aortic smooth muscle cells, we performed microarray expression 
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analysis on the 3 key stages of our directed differentiation: undifferentiated 
miPSCs (day 0), “lateral plate” Kdr+ mesoderm (day 5), and Acta2hrGFP+ and 
Acta2hrGFP- smooth muscle-like cells (day 13). Primary aortic smooth muscle cells 
(Acta2hrGFP+) were isolated from adult Acta2hrGFP mice and included as a positive 
control sample (Figure 2.8A). 
 
Principal component analysis (PCA) revealed changes in the global 
transcriptome of the different stages of mouse smooth muscle differentiation as 
the cells progress from undifferentiated miPSCs through Kdr+ mesodermal 
intermediates to Acta2hrGFP+ cells (Figure 2.8B). From the PCA plot, we also 
observe that the Acta2hrGFP+ cells and the Acta2hrGFP- cells cluster separately from 
each other, with the Acta2hrGFP+ cells clustering closer to the primary aortic 
smooth muscle population. Unsupervised hierarchical clustering of all 15 
samples using all genes with FDR q value < 1e-07 and absolute fold change > 5 
between any pairwise comparison revealed 10 different gene clusters, including 
clusters with gene signatures indicative of iPSC, lateral plate mesoderm, 
immature/synthetic smooth muscle, and mature/contractile smooth muscle 
populations (Figure 2.8C). These different clusters highlight the transcriptional 
changes that the cells undergo during the differentiation process. Day 0 (or 
undifferentiated) mouse iPSCs express common pluripotency markers such as 
Nanog, Xfp42, Dnmt3b, Klf5, Dppa4, and Dppa2. As the iPSCs differentiate 
towards Kdr+ mesodermal intermediates, they begin to lose expression of the 
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pluripotency markers. Instead, the Kdr+ mesodermal intermediates express high 
levels of Kdr, T (primitive streak), Foxf1 (lateral plate mesoderm), and Pdgfrb. 
Following specification in response to PDGF and TGF-β signaling, the 
Acta2hrGFP+ and Acta2hrGFP- cells express markers of immature/synthetic smooth 
muscle cells, including Acta2, Tagln, Col3a1, Col1a1, Pdgfrb, and Tpm1. The 
expression profile of the Acta2hrGFP+ and Acta2hrGFP- cells are similar, which could 
be due to being in the same differentiation media conditions as described in 
literature. However, the Acta2hrGFP+ cells express higher levels of the previously 
mentioned genes as well as other synthetic smooth muscle markers such as Eln, 
Myl9, Itgb5, Actg2, and Aebp1. Although they are still lowly expressed, 
contractile smooth muscle markers (Tpm2, Itga8, Ecm1, Cnn1, Smtn, and 
Myh11) are more highly expressed in the Acta2hrGFP+ cells. The similarity 
between the Acta2hrGFP+ and Acta2hrGFP- cells could also be due to Acta2+ cells 
that do not express the hrGFP reporter as shown in Figure 2.6C. 
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Figure 2.8: Microarray profiling of primary aortic SMCs and key stages of 
Acta2hrGFP miPSC directed differentiation towards smooth muscle-like cells. A) 
Schematic showing set-up of microarray experiment. The following cell types 
were profiled using microarray expression analysis: undifferentiated miPSCs 
(D0), purified Kdr+ mesodermal progenitors (D5 Kdr+), purified Acta2hrGFP+ and 
Acta2hrGFP- cells (D13 GFP+ and D13 GFP-), and adult primary Acta2hrGFP+ aortic 
SMCs. B) Principal component analysis (PCA) plot showing clustering of the 
samples. C) Unsupervised hierarchical clustering of microarray data using all 
genes with FDR q-value <1e-07 and absolute fold change >5 revealed 10 
different clusters. Four clusters of interest (mature/contractile SMC, 
immature/synthetic SMC, mesoderm, iPSC) were identified and key genes found 
within the clusters are shown to the right. 
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When looking at several differentially expressed genes (FDR q-value <0.05) 
between the Acta2hrGFP+ population or the aortic SMC population and the Kdr+ 
population, a majority of genes are commonly upregulated or downregulated 
(Figure 2.9A). Similarly a majority of transcription factors that are differentially 
expressed (FDR q-value <0.05) are common between the comparisons of in vitro 
and in vivo Acta2hrGFP+ populations to Kdr+ populations (Figure 2.9B). We wanted 
to understand what signaling pathways are changing during specification of our 
Acta2hrGFP+ cells and how similar these cells are to primary aortic smooth muscle 
cells so we ran GSEA analysis comparing both the iPSC-derived Acta2hrGFP+ 
population and the primary aortic Acta2hrGFP+ population to a common 
comparator, the Kdr+ population. Both comparisons showed the top 5 enriched 
gene sets to be “epithelial mesenchymal transition”, “hypoxia”, “myogenesis”, 
“coagulation”, and “TNFA signaling via NFKB” (Figure 2.9C). In addition, both 
comparison showed enrichment of “angiogenesis” and “TGFbeta signaling” gene 
sets. When looking at the top enriched genes within the “myogenesis” gene set in 
the Acta2hrGFP+ vs. Kdr+ comparison, a majority of the genes (11/16) are also 
highly expressed in aortic smooth muscle cells, such as Col3a1, Aebp1, Tagln, 
and Myom1 (Figure 2.9D, left). However, cardiomyocyte markers, Tnnt2 and 
Tnni1, are highly expressed in the in vitro Acta2hrGFP+ cells, but lowly expressed 
in primary aortic SMCs. As shown in Figure 2.7, we see approximately 1-2% of 
Tnnt2+ cells in the Acta2hrGFP+ population, which could contribute to the higher 
expression of Tnnt2 in our in vitro differentiated cells. In the top enriched genes 
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of the “myogenesis” gene set in the aortic SMC vs. Kdr+ comparison, we 
observed more contractile markers, such as Myh11 and Smtn, being highly 
expressed in the aortic SMCs, but lowly expressed in the iPSC-derived 
Acta2hrGFP+ population (Figure 2.9D, right). 
 
Although the in vitro and in vivo Acta2hrGFP+ populations appear similar when both 
are compared to the Kdr+ mesodermal population, 7,571 genes are differentially 
expressed (3,127 upregulated in aortic SMC and 4,444 downregulated in aortic 
SMC, FDR q-value <0.05) between the two populations. Myh11, a contractile 
SMC marker, and Myocd, a SMC transcriptional co-activator, are both found in 
the top differentially expressed genes and transcription factors when comparing 
primary aortic SMCs to iPSC-derived Acta2hrGFP+ cells (Figure 2.9E and 2.9F). In 
addition, GSEA analysis comparing the two populations reveals enrichment of 
cell cycle and proliferation gene sets in the in vitro Acta2hrGFP+ population (Figure 
2.9G). GSEA analysis also revealed enrichment of “IL6 JAK STAT3 Signaling” 
and “Notch Signaling” gene sets in the aortic SMCs compared to the iPSC-
derived Acta2hrGFP+ cells. 
 
 
 
 
  43 
 
Figure 2.9: Comparison of miPSC-derived Acta2hrGFP+ cells and primary aortic 
SMCs. A and B) Differentially expressed genes and transcription factors, 
respectively, with FDR q-value <0.05 when comparing Acta2hrGFP+ cells and 
aortic SMCs to Kdr+ mesodermal progenitors. Numbers outside the circles 
represent number of genes differentially expressed between Acta2hrGFP+ vs. Kdr 
and Aorta vs. Kdr+ comparisons. Number in the intersection of circles represents 
the number of overlapping genes between the comparisons. C) GSEA analyses 
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of Acta2hrGFP+ cells and aortic SMCs compared to Kdr+ mesodermal progenitors. 
D) Heat maps of top enriched genes in the “Myogenesis” gene set from the 
GSEA analyses comparing Acta2hrGFP+ and Kdr+ populations (left) or aortic SMC 
and Kdr+ populations (right). E and F) Top differentially expressed genes and 
transcription factors, respectively, between Acta2hrGFP+ cells and aortic SMCs. G) 
GSEA analysis showing enriched gene sets when comparing Acta2hrGFP+ cells 
and aortic SMCs. 
 
2.4 Discussion and Future Directions 
Our results demonstrate the generation of a mouse Acta2hrGFP reporter iPSC line 
that enriches for smooth muscle-like cells during the directed differentiation 
protocol. Specifically, we see enrichment of characteristic smooth muscle 
markers (Acta2, Tagln, Myh10, Myh11, Col1a1, and Eln) in our Acta2hrGFP+ 
population. We utilized known signaling pathways in in vivo development to 
pattern our cells to a Kdr+ mesodermal progenitor, which was enriched for a 
lateral plate mesoderm marker, Foxf1. Furthermore, we profiled the 
transcriptome of different stages of the smooth muscle cell directed differentiation 
protocol in comparison to primary aortic SMCs. The Acta2hrGFP+ population and 
the Acta2hrGFP- populations look similar transcriptomically, which could be due to 
the hrGFP reporter not marking all Acta2+ cells or the two populations coming 
from a directed differentiation where they were exposed to the same media. 
Recent literature has shown that media drives most of the transcriptomic 
changes174. 
 
Transcriptional profiling of the Acta2hrGFP+ cells also showed that the iPSC-
derived population has an expression profile with high expression of immature / 
  45 
synthetic SMC markers but low expression of mature/contractile markers. Many 
of the contractile markers are significantly lower in the in vitro Acta2hrGFP+ cells 
than in the aortic SMCs. GSEA analysis also showed enrichment of Notch 
signaling and Jak-Stat signaling pathways in the primary aortic SMC compared to 
the in vitro Acta2hrGFP+ cells, while gene sets associated with proliferation and cell 
cycler were enriched in the iPSC-derived Acta2hrGFP+ population. Future work will 
utilize different strategies to enhance expression of contractile marker genes in 
our iPSC-derived Acta2hrGFP+ cells. Many different methods have been published 
in the literature, ranging from chemical to mechanical cues. Mechanical 
stretching and conditioning of our Acta2hrGFP+ cells can be explored as a method 
for increasing contractile marker expression. We can also interrogate different 
pathways, specifically activation of Notch signaling and Jak-Stat signaling or 
withdrawal of PDGF signaling in our directed differentiation protocol and 
characterize the Acta2hrGFP+ cells for contractile marker expression.  
 
We also quantified the presence of cardiomyocytes present in the Acta2hrGFP+ 
population, since Acta2 is also a marker of cardiomyocytes. We observed that a 
small percent of the Acta2hrGFP+ population expresses Tnnt2, a cardiomyocyte 
marker, in both serum-free and serum-containing differentiation media. This low 
level presence of cardiomyocytes presumably explains results from our 
microarray profiling, where our in vitro Acta2hrGFP+ cells also shows high 
expression of Tnnt2 and Tnni, which are not seen in the transcriptional profile of 
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primary aortic SMCs. Besides cardiomyocytes, myofibroblasts are another cell 
type that expresses Acta2. In addition, myofibroblasts have transcriptional 
profiles that are fairly similar to smooth muscle cells, and they have similar 
functional properties including contraction or force generation and ECM 
production. In order to address the heterogeneity of the Acta2hrGFP+ population in 
our directed differentiation, single cell RNA sequencing can be performed to 
identify possible cell types within our differentiation. 
 
In summary, this study using the Acta2hrGFP reporter mouse iPSC line has 
allowed for isolation of a population enriched for smooth muscle markers. These 
cells provide an alternative source of smooth muscle-like cells for tissue 
engineering applications. In addition, we identified signaling pathways that have 
been described in vivo in smooth muscle cell development. These signaling 
pathways can be interrogated in our in vitro to study their effect on the maturation 
of our putative smooth muscle-like cells to a more mature / contractile phenotype. 
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CHAPTER 3: GENERATION OF HUMAN ACTA2eGFP REPORTER iPSC 
SYSTEM FOR DERIVATION AND ISOLATION OF SMOOTH MUSCLE-LIKE 
CELLS 
 
3.1 Introduction 
Smooth muscle cells have been implicated in cardiovascular diseases, such as 
atherosclerosis and pulmonary arterial hypertension. Atherosclerosis often leads 
to stenosis of the vessels, which require bypass grafts10-13. In the absence of 
autologous grafts, synthetic or tissue engineered grafts are utilized; however, 
tissue engineered grafts would need an autologous cell source to minimize 
immunogenic responses. Therefore, a human iPSC system for generating and 
isolating putative smooth-muscle like cells would provide an alternative source of 
cells for tissue engineering applications. Furthermore, the role of smooth muscle 
cells in pulmonary arterial hypertension (PAH) is not very well understood185-188. 
BMPR2 mutations have been linked to hereditary pulmonary arterial 
hypertension (HPAH), so the development and characterization of a reporter 
system for studying smooth muscle cells would provide a model system for 
studying the etiology of this complex disease in patient-specific backgrounds. We 
therefore generated a reporter human induced pluripotent stem cell line for 
deriving and isolating putative smooth muscle-like cells. Since ACTA2 is one of 
the earliest markers of smooth muscle cells and we had characterized 
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Acta2hrGFP+ cells in a miPSC system, we chose to target the ACTA2 locus with a 
reporter. 
 
Here, we describe the generation of an ACTA2eGFP reporter human induced 
pluripotent stem cell line, which faithfully enriches for a population expressing 
ACTA2 as well as other characteristic markers of smooth muscle cells. The work 
here follows developmental pathways as previously described in the mouse 
system in Chapter 2 to pattern iPSCs through a KDR+ mesodermal progenitor to 
an ACTA2+ smooth muscle-like cell. We also described transcriptomic analysis 
of ACTA2eGFP+ and ACTA2eGFP- populations in our directed differentiation 
protocol, where the ACTA2eGFP+ population is enriched for SMC markers. This 
system provides a tool for generating clinically relevant iPSC-derived smooth 
muscle-like cells for tissue engineering applications, and it also provides a 
platform to better study smooth muscle cell development and disease models. 
 
3.2 Methods 
Some methods used to generate the results in this section, including quantitative 
real time PCR, are described in Chapter 2. 
 
Generation of Knock-in ACTA2eGFP Human iPSC Reporter System for 
Isolation of Smooth Muscle-like Cells 
An ACTA2eGFP reporter human iPSC line was generated using the CRISPR-cas9 
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system previously described in literature173. In brief, guide RNAs targeting the 
stop codon of the ACTA2 gene was designed and cloned into the pSpCas9(BB)-
2A-GFP plasmid, a gift from Feng Zhang (Addgene plasmid #48138). A donor 
vector containing homology arms to the tenth exon and the 3’UTR of the ACTA2 
gene, P2A-eGFP, and a Puromycin resistance cassette flanked by loxP sites was 
also generated using molecular cloning techniques (see Figure 3.1). The 
pSpCas9/gRNA plasmid and the donor plasmid were introduced using 
nucleofection into undifferentiated human induced pluripotent stem cells 
maintained on Matrigel-coated plates in mTeSR (Stem Cell Technologies) using 
the Lonza P1 system. After nucleofection, puromycin-resistant clones were 
mechanically isolated and plated into fresh Matrigel-coated plates for clonal 
expansion and screening. Targeted cells were confirmed by PCR screening 
using primers binding outside of the 5’ homology arm and within the eGFP region 
as well as using primers binding within the Puromycin cassette and outside of the 
3’ homology arm. In addition, primers within the homology arms were used to 
screen for mono-allelic or bi-allelic targeting of the ACTA2 locus. The 5’ 
homology arm region as also sequenced to confirm proper targeting with the 
eGFP reporter. Targeted clones were transfected using Lipofectamine 
(ThermoFisher) with a Cre-Neo plasmid and underwent G418 selection to excise 
the Puromycin-resistance cassette. Excision of the antibiotic selection cassette 
was confirmed using PCR screening. Both a Cre-excised mono-allelic and a Cre-
excised bi-allelic targeted wild type human iPSC line were characterized using 
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pluripotent staining and karyotype analysis (Cell Line Genetics, Madison, WI) and 
used for all directed differentiation experiments towards smooth muscle-like cells. 
Human iPSC lines were maintained in a feeder-free culture system on growth 
factor reduced Matrigel (Corning)-coated plates in mTeSR1 medium (Stem Cell 
Technologies, Vancouver, Canada) and passaged using Gentle Cell Dissociation 
Reagent (Stem Cell Technologies).  
 
Directed Differentiation of Human iPSCs Towards ACTA2eGFP+ Population of 
Smooth Muscle-Like Cells 
Human iPSCs and were differentiated through a mesodermal progenitor 
expressing KDR and then further specified towards a smooth muscle-like lineage 
based on previously described literature157,159. Briefly, hiPSCs were single cell 
dissociated onto fresh Matrigel-coated plates in mTeSR supplemented with Y-
27632 for 48 hours prior to directed differentiation. Human iPSCs were then 
treated with Stemline II Hematopoietic Stem Cell Expansion media (Sigma) 
supplemented with 10 ng/mL each of BMP4, Activin A, VEGF, and FGF2 (R&D 
System) for 24 hours, followed by 72 hours of treatment with 10 ng/mL each of 
BMP4, VEGF, and FGF2 to reach a KDR+ mesodermal progenitor population. 
Mesodermal intermediates were dissociated and passaged in small clumps onto 
fresh Matrigel-coated plates in cSFDM (as described previously in Chapter 2) 
supplemented with 10 ng/mL of PDGF-BB (Invitrogen) and 10 ng/mL of human 
TGF-β (R&D Systems). Cells were dissociated and flow sorted using a FACSAria 
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or MoFlo Legacy (Beckman Coulter, Brea, CA) at the Boston University Medical 
Center Flow Cytometry Core based on GFP expression for further analysis 
between days 20-30. 
 
Microarray Profiling of Human iPSC-Derived ACTA2eGFP+ and ACTA2eGFP- 
Populations 
RNA was extracted using a QIAzol Lysis Reagent (Qiagen, Venlo, Netherlands) 
for purified ACTA2eGFP+ and ACTA2eGFP- populations from day 30 of 
differentiation. The ACTA2eGFP+ and ACTA2eGFP- were profiled using the 
Affymetrix® Human Gene 2.0 ST Array platform at the Boston University 
Microarray Core. The Human Gene 2.0 ST CEL files were normalized to produce 
gene-level expression values using the implementation of the Robust Multiarray 
Average (RMA)195 in the affy package (version 1.36.1)196 included in the 
Bioconductor software suite (version 2.12)197 and an Entrez Gene-specific 
probeset mapping (17.0.0) from the Molecular and Behavioral Neuroscience 
Institute (Brainarray) at the University of Michigan198,199. Array quality was 
assessed by computing Relative Log Expression (RLE) and Normalized 
Unscaled Standard Error (NUSE) using the affyPLM package (version 1.34.0)200. 
Principal Component Analysis (PCA) was performed using the prcomp R function 
with expression values that had been normalized across all samples to a mean of 
zero and a standard deviation of one. Differential expression was assessed using 
the moderated (empirical Bayesian) ANOVA and t test implemented in the limma 
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package (version 3.14.4) (i.e., creating simple linear models with lmFit, followed 
by empirical Bayesian adjustment with eBayes). Correction for multiple 
hypothesis testing was accomplished using the Benjamini-Hochberg false 
discovery rate (FDR)201. All microarray analyses were performed using the R 
environment for statistical computing (version 2.15.1). 
 
Gene Set Enrichment Analysis 
Gene set enrichment analysis was performed on the microarray dataset203,204. 
Briefly, GSEA (version 2.2.1) was performed using MSigDB v6.0 hallmark gene 
sets (http://software.broadinstitute.org/gsea/index.jsp) on our microarray 
database comparing the ACTA2eGFP+ and ACTA2eGFP- populations from our 
human iPSC directed differentiation. The genes were ranked according to the t 
statistic computed between the ACTA2eGFP+ and ACTA2eGFP- populations, and 
the ranked list was used to perform pre-ranked GSEA analyses. Significant 
pathways were considered those with Benjamini-Hochberg false discovery rate 
FDR q-value < 0.1. 
 
3.3 Results 
Generation of hiPSC-derived ACTA2eGFP+ cells 
The reporter mouse iPSC system allowed us to purify a more pure population of 
Acta2+ cells; however, the transgenic reporter was not 100% faithful and did not 
mark all Acta2+ cells. In order to address that issue, we used CRISPR-cas9 gene 
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editing strategies to target an enhanced green fluorescent protein reporter 
(eGFP) to the endogenous human ACTA2 locus in a wild type human iPSC line, 
which would give us a tool for the identification and purification of ACTA2+ cells. 
Since smooth muscle alpha actin functions in cell movement and contraction of 
muscles in smooth muscle cells, we targeted an exon10-P2A-eGFP cassette to 
the stop codon of ACTA2 (Figure 3.1). This targeting strategy was designed to 
allow for translation of both ACTA2 and the eGFP reporter in an effort to avoid 
haploinsufficiency. The ACTA2eGFP reporter hiPSC line (BU3-ACTA2eGFP) 
underwent successful mono-allelic (BU3 AG8Cr1) and bi-allelic integration (BU3 
AG18Cr1) of the donor template by PCR screening, and sequencing revealed the 
replacement of the stop codon with the P2A-peptide and eGFP reporter. Both the 
mono-allelic and bi-allelic human iPSC lines were characterized with a normal 
karyotype and used for further experiments. 
 
 
Figure 3.1: Schematic showing targeting strategy to knock-in eGFP reporter to 
the human ACTA2 locus using the CRISPR-cas9 system. 
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Figure 3.2: Schematic of human induced pluripotent stem cell differentiation 
towards smooth muscle-like cells. 
 
To differentiate the reporter hiPSC line, we followed similar developmental 
pathways and strategies as in the mouse iPSC system. Protocols for deriving 
KDR-expressing mesoderm from our lab and others were tested. To generate a 
mesodermal precursor, we treated our cells with 10 ng/mL each of BMP4, VEGF, 
FGF2, and Activin A for 24 hours, followed by 72 hours with BMP4, VEGF, and 
FGF2 (Figure 3.2). When following the kinetic of mesoderm induction, we see an 
early ACTA2eGFP+/KDR- population arise. As the cells start to express KDR, the 
ACTA2eGFP reporter turns off, giving rise to ACTA2eGFP-/KDR+ population of 
mesodermal precursors (Figure 3.3A). On day 4, we see 30-80% KDR+ cells, 
which are enriched for a lateral plate mesoderm marker, FOXF1 (Figure 3.3B).  
ACTA2eGFP+ cells isolated on day 30 of the differentiation expressed the 
characteristic smooth muscle markers (ACTA2, TAGLN, COL1A1, ELN, and 
MYH11). ACTA2 and TAGLN were expressed at similar levels when compared to 
a primary SMC control (Figure 3.4). In addition, COL1A1 and ELN were more 
highly expressed in the ACTA2eGFP+ cells than in the primary SMC control, while 
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MYH11 was more lowly expressed in the ACTA2eGFP+ cells compared to the 
primary SMC control. This indicates that the hiPSC-derived ACTA2eGFP+ smooth 
muscle-like population might also have a more immature / synthetic phenotype, 
similar to our observations from the miPSC-derived Acta2hrGFP+ population.   
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Figure 3.3: Characterization of KDR mesodermal progenitors. A) Kinetic of KDR 
expression during the directed differentiation towards mesodermal progenitors 
using both mono-allelic (BU3 AG8Cr1) and bi-allelic (BU3 AG18Cr1) targeted 
hiPSC lines. There is an initial KDR- ACTA2eGFP+ population that arises. By day 
4, a KDR+, ACTA2eGFP- population arises. B) Gene expression of mesodermal 
markers in KDR+ and KDR- populations in both mono-allelic and bi-allelic 
targeted hiPSC lines. 
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Figure 3.4: Characterization of ACTA2eGFP populations on day 30 of directed 
differentiation. A) Flow cytometry plot of ACTA2eGFP expression. GFP+ gate is 
based off of wild type iPSC-line without ACTA2eGFP reporter. B) Gene expression 
of characteristic markers of SMCs in ACTA2eGFP+ and ACTA2eGFP- cells. RT-
qPCR measurements of fold change (2-ΔΔCt) of mRNA expression is shown for 
GFP+, GFP-, and primary airway SMC populations. Undifferentiated hiPSC 
mRNA expression is defined as fold change = 1. Bars represent ± S.D. * p≤0.05 
and ** p≤0.01 by unpaired two-tailed Student’s t-test between GFP+ and GFP- 
populations. 
 
Transcriptomic Profile of ACTA2eGFP+ and ACTA2eGFP- Populations 
To characterize the transcriptomic profile of the ACTA2eGFP+ and Acta2eGFP- cells, 
we performed microarray analysis on the two populations isolated on Day 30 of 
the directed differentiation (Figure 3.5A). PCA analysis reveals that the 
ACTA2eGFP+ and Acta2eGFP- cells cluster separately (Figure 3.5B). When looking 
at characteristic SMC markers, including ACTA2, TAGLN, MYH10, CNN1, 
SMTN, and MYH11, these genes are consistently upregulated in the ACTA2eGFP+ 
cells compared to the ACTA2eGFP- cells (Figure 3.5C).  Using a more unbiased 
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approach, the top differentially upregulated genes in the ACTA2eGFP+ cells 
include smooth muscle actins (ACTA2 and ACTG2) as well as collagens 
(COL8A1 and COL12A1) (Figure 3.5D). Furthermore, MYOCD, a transcription 
co-activator of the SMC lineage, is found in the top 10 upregulated transcription 
factors in the ACTA2eGFP+ population. GSEA analysis also reveals similar gene 
sets to the GSEA analysis of the mouse microarray, including “myogenesis”, 
“TGFbeta signaling”, and “angiogenesis” (Table 3.1). Top enriched genes in the 
“myogenesis” gene set include TAGLN, TPM2, MYH9, COL1A1, and COL3A1 
(Figure 3.6). 
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Figure 3.5: Microarray profiling of ACTA2eGFP+ and ACTA2eGFP- cells on day 30 of 
directed differentiation. A) Schematic of microarray experiment. B) Principal 
component analysis (PCA) plot of ACTA2eGFP+ and ACTA2eGFP- populations. C) 
Heat map of selected smooth muscle cell marker genes. D) Heat map of top 25 
differentially expressed genes with FDR q-value <0.05 between ACTA2eGFP+ and 
ACTA2eGFP- populations. 
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Table 3.1: GSEA analysis showing enriched gene sets in ACTA2eGFP+ cells 
compared to ACTA2eGFP- cells. 
 
 
Figure 3.6: Heat map of top enriched genes in the “Myogenesis” gene set from 
the GSEA analysis comparing ACTA2eGFP+ and ACTA2eGFP- populations. 
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3.4 Discussion and Future Directions 
Our results demonstrated the generation of a human ACTA2eGFP reporter iPSC 
line that enriches for smooth muscle-like cells during the directed differentiation 
protocol. We see enrichment of characteristic smooth muscle markers (ACTA2, 
TAGLN, COL1A1, ELN, and MYH11) in our Acta2eGFP+ population. We utilized 
known signaling pathways to pattern our cells to a KDR+ mesodermal progenitor, 
which was enriched for a lateral plate mesoderm marker, FOXF1. During 
patterning to the KDR+ mesodermal precursor, we observed an early 
ACTA2eGFP+ KDR- population, which was enriched for ACTA2 but not KDR. In 
addition it was relatively depleted of FOXF1, PAX2, and TBX6 compared to 
KDR+ and double negative populations.  
 
Furthermore, we profiled the transcriptome of our ACTA2eGFP+ and ACTA2eGFP- 
cells. The ACTA2eGFP+ cells and ACTA2eGFP- cells cluster separately from each 
other with the ACTA2eGFP+ cells expressing higher levels of characteristic smooth 
muscle cell markers. When compared to a primary SMC control, MYH11, a 
contractile marker of SMCs, was expressed at low levels in our hiPSC-derived 
ACTA2eGFP+ cells. Similar to the miPSC system, the hiPSC-derived putative 
smooth muscle-like cells may have a more immature / synthetic phenotype. In 
addition, GSEA analysis revealed that mesenchymal related gene sets, including 
“myogenesis”, “angiogenesis”, and “epithelial mesenchymal transition” are 
enriched in the ACTA2eGFP+ population. Many of the top enriched genes in these 
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gene sets are characteristic smooth muscle cell markers, including ACTA2, 
TAGLN, and MYH11. Signaling pathway gene sets, “TGFbeta signaling” and 
“TNFA signaling”, are also enriched in the ACTA2eGFP+ population. TNFα 
signaling promotes proliferation and migration of smooth muscle cells through 
signaling mechanisms that can overlap with PDGF signaling189,190, which is being 
activated in our directed differentiation protocol. This indicates that the 
ACTA2eGFP+ population has a more immature / synthetic phenotype. The 
withdrawal of PDGF signaling from the directed differentiation protocol may lead 
to enhancement of mature / contractile smooth muscle markers. Future 
experiments will interrogate different chemical and mechanical cues to enhance 
expression of contractile markers in the hiPSC-derived ACTA2eGFP+ 
populations56. 
 
As described in the Chapter 2, ACTA2 is also expressed in cardiomyocytes and 
myofibroblasts56,57; however, we have not quantified the presence of 
cardiomycytes in our hiPSC directed differentiation. Our microarray profiling of 
the ACTA2eGFP+ population shows low levels of expression of cardiomyocyte 
markers, TNNT2, TNNI, and NKX2-5, which suggests that there is little to no 
cardiomyocytes in our ACTA2eGFP+ population. Future experiments to profile 
gene expression on a single cell level will further identify any heterogeneity in our 
ACTA2eGFP+ population. Also, flow cytometry revealed a spectrum of fluorescent 
intensity of the GFP reporter (Figure 3.4), indicating a range of ACTA2 
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expression. Single cell gene expression profiling may help to identify whether 
high or medium expression levels of ACTA2 and the GFP reporter correspond to 
a smooth muscle cell, cardiomyocyte, or myofibroblast phenotype. 
 
To summarize, we described the generation of an ACTA2eGFP reporter hiPSC 
line, which allowed for isolation of a population enriched for smooth muscle 
markers. These cells provide a clinically relevant alternative source of smooth 
muscle-like cells for tissue engineering applications.  Furthermore, these cells 
can be used to better understand signaling pathways involved in SMC 
development and specification. In addition, this reporter-based hiPSC system 
can be utilized to study the role of smooth muscle cells in hereditary pulmonary 
arterial hypertension due to BMPR2 mutations. We have already used our 
CRISPR-cas9 targeting strategy to introduce an eGFP reporter to the ACTA2 
locus in BMPR2 mutation hiPSC lines (pre- and post-correction) and performed 
preliminary directed differentiations to generate ACTA2eGFP+ cells; however, the 
issues of mature/contractile markers and heterogeneity in the ACTA2eGFP+ cells 
need to be addressed before utilizing this system in a disease model. Also, the 
identification and validation of cell surface markers using the transcriptomic 
profiles will allow for isolation of a smooth muscle-like population without 
introduction of a GFP reporter.   
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CHAPTER 4: CHARACTERIZATION OF iPSC-DERIVED SMOOTH MUSCLE-
LIKE CELL SHEETS AS FUNCTIONAL BUILDING BLOCKS FOR TISSUE 
ENGINEERING APPLICATIONS 
 
4.1 Introduction 
Current tissue engineered blood vessel replacements have many limitations, 
including immunogenic response, mechanical mismatch, and restenosis. In order 
to design a suitable, clinically relevant blood vessel replacement, TEBVs must 
address the issues of cell source and tissue structure / mechanical behavior. The 
native blood vessel displays anisotropic non-linear behavior when its mechanical 
properties are assessed through a uniaxial tensile test. 
 
Native blood vessels are composed of three layers, with the medial layer being 
comprised of multiple layers of aligned smooth muscle cells as well as collagen 
and elastin40,41. Each layer of smooth muscle cells exhibits differential alignment 
orientations. Cell sheet engineering techniques allows for non-damaging cell 
detachment of cell sheets, allowing for maintenance of cell-cell junctions and 
extracellular matrix proteins. Furthermore, soft lithography techniques to 
generate micropatterns allow for alignment of cells within the cell sheets162,163. 
Therefore, we wanted to develop a system which can generate building blocks of 
a non-immunogenic tissue-engineered blood vessel that mimics the structure and 
mechanical behavior of native blood vessels. 
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Here, we describe the generation of iPSC-derived smooth muscle-like cell sheets 
using a micro-patterned enzyme-degradable hydrogel system. We generated 
aligned cell sheets from both Acta2hrGFP+ and Acta2hrGFP- populations, which 
displayed non-linear behavior reminiscent of native blood vessel mechanics. This 
system allows for generation of functional iPSC-derived cell sheet building 
blocks, which can then be built into a function blood vessel replacement. 
 
4.2 Methods 
Hydrogel Substrate and Cell Sheet Fabrication 
Tyramine-conjugated carboxymethyl-cellulose (CMC-ty) and alginate (Al-ty) were 
synthesized as previously described in literature (Figure 4.1). In brief, 
carboxymethylcellulose sodium salt (CMC-Na) or alginate sodium salt (Al-Na)  
(Sigma) were dissolved in 2-(N-morpholino)ethanesulfonic acid (MES) buffer 
(Alfa Aesar™, Tewksbury, MA) for 24 hours with stirring. N-hydroxysuccinate 
(NHS) (Sigma), N-(3-Dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride 
(EDC) (Sigma), and Hydroxybenzotriazole monohydrate (HOBt) (only for CMC-ty 
reaction) (Chem-Impex Internation Inc., Wood Dale, IL) were then added and 
stirred for 2 hours. Tyramine hydrochloride (Sigma) was then added and stirred 
for 24 hours. The CMC-ty or Al-ty polymer solution was then transferred to Slide-
A-Lyzer™ Dialysis Cassettes (ThermoFisher) and dialyzed with distilled water for 
72 hours, changing the distilled water every 12 hours. After dialysis, the sample 
was lyophilized and then resuspended in Krebs-Ringer Bicarbonate Buffer 
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(Boston Bioproducts, Worcester, MA) at 1.5 wt% and filtered through 1 μm pore 
size syringe filter before use.  
 
To generate micropatterned hydrogel substrates, established photolithography 
and soft lithography techniques were used to generate patterned silicon wafer 
molds, patterned polydimethylsiloxane (PDMS) molds, and patterned gelatin 
molds. In brief, a 5 μm layer of SU8-5 negative photoresist (Microchem, Newton, 
MA) was spin-coated onto silicon wafers and soft baked at 65°C and 95°C. The 
photoresist was cross-linked using exposure to UV light through a patterned 
mask, containing multiple parallel lines that were 30 μm wide with 30 μm of 
spacing between lines. The silicon wafer was washed in developer solution to 
remove the un-crosslinked photoresist to form the master mold for generating 
patterned PDMS molds. PDMS at a ratio of 10:1 base to curing agent was 
poured onto the master silicon wafer mold, degassed, and cured overnight at 
80°C. The patterned PDMS was removed from the wafer and cut to the desired 
dimensions and sterilized using 70% ethanol and UV. A 10 wt% gelatin in PBS 
solution was poured over the patterned PDMS molds in a tissue culture plate. 
After cooling the gelatin at 4°C, the gelatin was cut and flipped over to form a 
gelatin mold with a trough containing the desired pattern. 
 
After making the gelatin molds, the hydrogel substrates were synthesized using 
the previously made 1.5 wt% CMC-ty or Al-ty polymer solutions (Figure 4.1). 1 
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mL of CMC-ty or Al-ty solution was mixed with 1 μL of a 1unit/μL horseradish 
peroxidase (HRP) solution in Krebs-Ringer buffer. The polymer solution with 
HRP was added into the patterned trough of the gelatin mold, covered with a 
dialysis membrane, and cross-linked by adding a 0.15 wt% hydrogen peroxide 
(H2O2) solution in Krebs-Ringer buffer on top of the dialysis membrane for 30 
minutes at 4°C. After polymerization, the dialysis membrane was removed, and 
the gelatin mold was dissolved using warm PBS. Following multiple washes, the 
CMC-ty or Al-ty hydrogel substrates were flipped over and placed in tissue 
culture plates for generation of cell sheets. 
  
Hydrogel substrates were coated using rat tail collagen type I before seeding with 
iPSC-derived smooth muscle-like cells or a control immortalized mouse aortic 
smooth muscle cell line, MOVAS (ATCC, Manassas, VA). Cells were cultured 
using complete media contained DMEM, 10% FBS, L-glutamine, and primocin.  
 
Mechanical Characterization of Cell Sheets 
To characterize the mechanical properties, we utilized a custom-built uniaxial 
tensile tester, previously developed177. In brief, the tensile tester was comprised 
of a test cell, linear actuator, and force sensor (Figure 4.2). The force sensor is 
composed of a cantilever beam with a Hall-Effect magnetic field sensor at one 
end and a sample attachment mount in the middle. The Hall-Effect sensor is 
situated in a magnetic yoke composed of 4 magnets. The linear actuator is 
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connected to another sample attachment mount. The linear actuator is used to 
stretch the sample, which will cause the beam to deflect. The Hall-Effect sensor 
will measure the beam tip displacement, and the subsequent force 
measurements are collected. 
 
Cells sheets were harvested using a hydrogel-specific enzymatic digestion 
process. Cell sheets were trimmed, measured, and mounted onto the tensile 
tester in a PBS bath. The tensile tester was adjusted to a position such that the 
cell sheets were in a zero-strain state, where they began to bear load. The 
mechanical properties of the cell sheets were then characterized by stretching to 
failure at a strain rate of 0.033/s after being subject to 3 pre-stress loading cycles 
up to 20% engineering strain. Mechanical properties, including Young’s modulus, 
failure stress, and failure strain, were determined from the measured stress-
strain values. Young’s modulus was calculated based off the slope of a linear fit 
of the initial linear region of the stress-strain curves.  
 
Collagen and Elastin Quantification 
To measure extracellular matrix composition, cell sheets were harvested through 
a hydrogel-specific enzymatic digestion process and tested using a Sircol™ 
Soluble Collagen Assay (Biocolor, Carrickfergus, Ireland) and a Fastin™ Elastin 
Assay (Biocolor, Carrickfergus, Ireland). Briefly, harvested cell sheets were 
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weighed prior to undergoing sample preparation for collagen or elastin 
measurement.  
 
Figure 4.1: Schematic showing alginate-tyramine (Al-ty) substrate synthesis. A) 
Schematic showing reaction of alginate and tyramine in the presence of EDC and 
NHS to form alginate-tyramine. B) Schematic showing crosslinking process of 
alginate-tyramine using HRP and H2O2 to form alginate-tyramine hydrogels. 
Tyramine-conjugated carboxymethyl-cellulose hydrogels are generated using the 
same reactions, substituting carboxymethyl-cellulose for alginate. Adapted from 
Sakai and Kawakami (2007)168.  
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Table 4.1: Table showing reagents used to synthesize tyramine-conjugated 
carboxymethyl-cellulose (CMC-ty) and alginate (Al-ty). 
 
 
Figure 4.2: Schematic of uniaxial tensile tester developed by Backman et al. The 
uniaxial tensile tester is composed of three components: a linear actuator, a test 
cell, and a Hall-Effect force sensor. Adapted from Backman et al. (2017)177. 
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4.3 Results 
Smooth Muscle Cell Sheet Mechanical Characterization and Extracellular 
Matrix Quantification 
To test whether we can make functional building blocks for tissue engineering 
applications, we utilized previously published cell sheet engineering 
techniques169. We generated aligned cell sheets from mouse iPSC-derived 
Acta2hrGFP+ and Acta2hrGFP- populations (Figure 4.4A). Brightfield and fluorescent 
images indicate that the cells have aligned parallel to the micropatterned 
grooves. Expression of the GFP reporter is retained in the Acta2hrGFP+ cell 
sheets, and minimal expression of the GFP reporter is seen in the Acta2hrGFP- cell 
sheets. After culturing the cells to confluence, cell sheets were released through 
an enzymatic degradation of the hydrogel substrate and characterized using a 
uniaxial tensile tester177. Stress-strain curves (Figure 4.4B) were generated, with 
the cell sheets demonstrating non-linear behavior. Elastic modulus and ultimate 
tensile stresses were calculated for the Acta2hrGFP+ and Acta2hrGFP- cell sheets, 
with the Acta2hrGFP+ cell sheets having a higher ultimate tensile stress than the 
Acta2hrGFP- cell sheets.   
 
  72 
 
Figure 4.3: Schematic of alginate-tyramine hydrogel and cell sheet fabrication. A) 
Schematic of hydrogel-specific enzyme degradation strategy for cell sheet 
fabrication. B) Schematic of alginate-tyramine hydrogel fabrication using soft 
lithography techniques and generation of cell sheets using hydrogel substrates. 
 
 
Figure 4.4: Characterization of mechanical properties of cell sheets. A) Images of 
Acta2hrGFP+ and Acta2hrGFP- cell sheets 96 hours after seeding onto alginate 
tyramine hydrogel substrates. B) Representative stress-strain curves for 
Acta2hrGFP+ and Acta2hrGFP- cells sheets undergoing uniaxial tensile tests. C and 
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D) Elastic modulus and maximum stress of the Acta2hrGFP+ and Acta2hrGFP- cells 
sheets. Bars represent ± S.D. * p≤0.05 by unpaired two-tailed Student’s t-test 
between GFP+ and GFP- cell sheets. 
 
4.4 Discussion and Future Directions 
Our results demonstrated that we were able to generate mouse iPSC-derived cell 
sheets. The cell sheets displayed non-linear behavior, with the Acta2hrGFP+ cell 
sheets having higher ultimate tensile stresses than that of the Acta2hrGFP- cell 
sheets.  The cell sheets have an initial linear region similar to the behavior seen 
in native blood vessels47. The elastic moduli of this region in both the Acta2hrGFP+ 
and Acta2hrGFP- cell sheets were around 200 kPa, which is in the range of elastic 
modulus observed in bovine vascular smooth muscle cell sheets (~100 kPa)177. A 
study looking at the effect of age-related cross-linking of collagen in a diabetes 
model observed moduli of normal and diabetic vessels in the 2-8 MPa range207. 
Bergel measured elastic moduli in the range of 100 kPa to 2 MPa for carotid 
artery, thoracic aorta, femoral artery, and abdominal aorta208. Furthermore, native 
blood vessels undergo strain hardening at high stresses after transitioning from 
the elastic region to the plastic deformation region. The Acta2hrGFP+ and 
Acta2hrGFP- cell sheets display strain hardening behavior at high strains prior to 
failure. Both Acta2hrGFP+ and Acta2hrGFP- cell sheets were fully confluent; however, 
the number of cells in each cell sheet was not quantified. Studies have shown 
that mechanical properties of the blood vessel depend on the activation state of 
the smooth muscle cells49,54, so the number of cells could affect the mechanical 
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properties observed in the cell sheets. 
 
Although these preliminary studies demonstrate that we can generate cell sheets 
using miPSC-derived Acta2hrGFP+ cells, further studies using hiPSC-derived cells 
need to be performed to develop a clinically relevant model. Furthermore, the 
ECM content and structure of the cell sheets need to be characterized and 
compared to that of native blood vessels. Finally, blood vessel mechanical 
behavior is characterized by anisotropy; however, we have only tested our cell 
sheets in the direction of alignment. Previous studies have shown that aligned 
bovine smooth muscle cell sheets display anisotropic behavior162,163, but further 
studies will need to be done to characterize the mechanical behavior of our 
iPSC-derived cell sheets. Lastly, after characterizing single cell sheet mechanics 
of iPSC-derived cell sheets, layer-by-layer stacking strategies can be employed 
to generate a blood vessel replacement, which will also need to be characterized 
for functionality and efficacy. 
 
In summary, we generated aligned cell sheets from miPSC-derived Acta2hrGFP+ 
and Acta2hrGFP- populations. The cell sheets displayed non-linear mechanical 
behavior, and the Acta2hrGFP+ cell sheets had a higher ultimate tensile stress than 
than the Acta2hrGFP- cell sheets. This system allows for generation of functional 
building blocks from iPSC-derived populations that can be utilized to generate 
clinically relevant blood vessel replacements.  
  75 
CHAPTER 5: IDENTIFYING PRIMARY VASCULAR AND AIRWAY SMOOTH 
MUSCLE CELL GENE SIGNATURES IN THE ADULT MOUSE  
 
5.1 Introduction 
Smooth muscle cells function to regulate the tone of various vessels and organs 
in the body through contraction or relaxation of smooth muscle cell layers. 
Although extensive literature and research has characterized differences 
between synthetic and contractile smooth muscle phenotypes, most SMC 
phenotype research has been performed in a specific SMC subtype, such as 
vascular smooth muscle cells. There has been little research describing 
differences between or identifying unique gene signatures of specific SMC 
subtypes. For example, splice variants of Smtn have been shown to distinguish 
between visceral and vascular SMCs68,69. Notch3103,104 and Cspg4105 have also 
been shown to be able to distinguish between vascular and airway smooth 
muscle cells. Cspg4 and Acta2 co-expression is also restricted to the arterial and 
not the venous blood vessels106,107. Furthermore, gene expression profiles of 
human SMC subtypes were characterized and revealed differences in gene 
signatures; however, the SMCs were profiled after propagation in culture, which 
can affect the transcriptomic signatures.  
 
Smooth muscle cells have been shown to derive from different embryological 
origins, including lateral plate mesoderm, paraxial mesoderm, and neural crest93-
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100,140-142.  Many of these studies have been performed in studies of vascular 
smooth muscle cells; however, differences between airway and vascular smooth 
muscle cells have not been studied. Airway and lung vascular smooth muscle 
cells develop from lateral plate mesoderm, but many of these studies identify 
their iPSC-derived SMCs from lateral plate mesodermal intermediates as 
vascular smooth muscle cells without having comparisons to airway smooth 
muscle cells. Although studying smooth muscle cells from different embryological 
origins has implications in vascular smooth muscle disease, it is still unclear what 
smooth muscle subtype is being generated in iPSC directed differentiations since 
other non-vascular smooth muscle subtypes also derived from the same 
embryological origins. 
 
The identification of gene signatures of specific SMC subtypes will be critical in 
providing a roadmap for deriving SM-like cells of a specific subtype. In addition, 
identification of novel cell surface receptors in the SMC subtypes will allow for 
purification of specific subtype SMCs without using an engineered reporter 
system. Better purification or enrichment for specific SMC subtypes is an 
important step for building more specific disease models from patient-derived 
iPSC lines. In this study, we identify unique gene signatures of primary adult lung 
vascular and airway smooth muscle cells using a double-transgenic Acta2hrGFP 
Cspg4DsRed mouse to purify out vSMCs and aSMCs from an adult mouse lung for 
whole transcriptome profiling. We further compared our data to published 
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scRNA-seq data of adult lung mouse mesenchymal populations and identified a 
panel of unique markers of vSMCs or aSMCs that overlap between the data sets. 
Furthermore, we have validated Acta2 and Hhip co-expression as a specific 
marker of aSMCs in the adult mouse lung. This finding provides an expression 
profile of primary adult SMCs that can help determine what specific SMC subtype 
is generated in our iPSC differentiations. 
 
We also provide preliminary data showing the generation of a mouse iPSC line 
from the double-transgenic Acta2hrGFP Cspg4DsRed mouse and subsequently 
Acta2hrGFP+/Cspg4DsRed+ and Acta2hrGFP+/Cspg4DsRed- populations. This reporter 
line can be used in conjunction with the identified vSMC and aSMC gene 
signatures to better understand the role of different signaling pathways in the 
specification of specific SMC subtypes. 
 
5.2 Methods 
Some methods used to generate the results in this section, including quantitative 
real time PCR, miPSC line generation, and directed differentiation of miPSCs 
towards a smooth muscle-like Acta2hrGFP+ population, are described in Chapter 2. 
 
Acta2hrGFP/Cspg4DsRed Mouse for Isolation of Primary Adult Lung Vascular 
and Airway Smooth Muscle Cells and Cell Sorting 
A C57BL/6 double-transgenic fluorescent reporter mouse (Acta2hrGFP/Cspg4DsRed) 
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was generated by crossing a transgenic Acta2hrGFP and a transgenic Cspg4DsRed 
mouse105. All studies involving animals were carried out in accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
NIH, and the protocol was approved by the Boston University IACUC Committee. 
 
Adult mouse lungs were harvested between 3 and 6 months of age, and a cell 
suspension was obtained through mincing and enzymatic digestion of the lungs 
using dispase and collagenase (ThermoFisher)171. The right lung lobes were 
collected and digested together to make up each sample. Cells were further 
treated with Red Blood Cell Lysis Buffer (Sigma) and washed with PBS. The 
harvested cells were spun down at 300 RCF for 5 minutes at 4°C and re-
suspended in buffer containing 2% FBS and calcein blue AM (ThermoFisher) for 
live cell capture during flow cytometry. Live cells were sorted on a MoFlo Legacy 
(Beckman Coulter, Brea, CA) at the Boston University Medical Center Flow 
Cytometry Core Facility based on Acta2hrGFP/Cspg4DsRed expression 
(Acta2hrGFP+/Cspg4DsRed+ for vSMCs and Acta2hrGFP+/Cspg4DsRed- for aSMCs).  
 
Microarray Profiling of Primary Adult Lung vSMCs and aSMCs 
Microarray profiling was performed on adult lung vascular SMCs and airway 
SMCs using methods described in Chapter 2. In brief, RNA was extracted from 
purified vSMCs and aSMCs using a QIAzol Lysis Reagent (Qiagen, Venlo, 
Netherlands). Each RNA sample for the array study was RNA isolated from the 
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combined lobes of the right lung of one adult mouse. Three vSMC and aSMC 
samples were profiled along with three undifferentiated mouse iPSC samples 
(from Chapter 2) using the Affymetrix® Mouse Gene 2.0 ST Array platform at the 
Boston University Microarray Core. The Mouse Gene 2.0 ST CEL files were 
normalized to produce gene-level expression values using the implementation of 
the Robust Multiarray Average (RMA)195 in the affy package (version 1.36.1)196 
included in the Bioconductor software suite (version 2.12)197 and an Entrez 
Gene-specific probeset mapping (17.0.0) from the Molecular and Behavioral 
Neuroscience Institute (Brainarray) at the University of Michigan198,199. Array 
quality was assessed by computing Relative Log Expression (RLE) and 
Normalized Unscaled Standard Error (NUSE) using the affyPLM package 
(version 1.34.0)200. Principal Component Analysis (PCA) was performed using 
the prcomp R function with expression values that had been normalized across 
all samples to a mean of zero and a standard deviation of one. Differential 
expression was assessed using the moderated (empirical Bayesian) ANOVA and 
t test implemented in the limma package (version 3.14.4) (i.e., creating simple 
linear models with lmFit, followed by empirical Bayesian adjustment with 
eBayes). Correction for multiple hypothesis testing was accomplished using the 
Benjamini-Hochberg false discovery rate (FDR)201. Human homologs of mouse 
genes were identified using HomoloGene (version 68)202. All microarray analyses 
were performed using the R environment for statistical computing (version 
2.15.1). Gene signatures of vSMC and aSMC populations were identified using 
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the top 50 differentially expressed genes (FDR q-value <0.05) between the 
vSMC and aSMC populations using a moderated t test.  
 
To compare this microarray dataset, profiling vSMC and aSMC populations, with 
the aortic SMC microarray profiling performed in Chapter 2, the Mouse Gene 2.0 
ST CEL files were normalized together. All subsequent analyses were performed 
as described above. Gene signatures of vSMC, aSMC, and aoSMC populations 
were identified using moderated t tests between populations with FDR q-value 
<0.05 and fold change >|5|. 
 
Single Cell RNA-Sequencing Analysis of Adult Mouse Lung Mesenchymal 
Populations Data Set from Zepp et al. 
Single cell RNA-sequencing data of adult mouse lung mesenchymal populations 
from Zepp et al. (2017)171 was downloaded from the Gene Expression Omnibus 
(GEO: GSE99714) for re-analysis and comparison to our microarray database. 
Dimensionality reduction visualization was done via Weinreb et al.’s SPRING 
software (https://kleintools.hms.harvard.edu/tools/spring.html)172, using 50 PCA 
dimensions and a minimum coefficient of variation of 2.0. To visualize the 
expression of gene sets that define vSMC or aSMC populations, gene signatures 
from our microarray database (as described in the microarray profiling methods 
of this chapter) comparing vSMCs and aSMCs were entered into the SPRING 
web-tool. Briefly, the vSMC or aSMC gene signatures were identified as the top 
  81 
50 differentially expressed genes (FDR q-value <0.05) between the two 
populations using a moderated t test. To identify clusters that show expression of 
either vSMC or aSMC gene signature, the scRNA-seq data from Zepp et al. was 
analyzed using the Seurat package (version 2.2) in the R environment. The 
visualization of vSMC and aSMC gene sets in the SPRING web-tool and Seurat’s 
graph-based clustering algorithm were used to identify vSMC and aSMC clusters 
in the Zepp et al. data set. Differential expression was performed using the 
DESeq2 (version 2) package in the R environment to compare the identified 
vSMC and aSMC clusters (FDR <0.05). In addition, the SPRING web-tool was 
used to identify enriched genes in the vSMC and aSMC clusters. 
 
Gene Set Enrichment Analysis 
Gene set enrichment analysis203,204 was performed as described previously in 
Chapter 2. Briefly, GSEA was performed using MSigDB v6.0 hallmark gene sets 
(http://software.broadinstitute.org/gsea/index.jsp) on our microarray database 
comparing the vSMC and aSMC populations of the adult mouse lung. The genes 
were ranked according to the t statistic computed between vSMCs and aSMCs, 
and the ranked list was used to perform pre-ranked GSEA analysis. Significant 
pathways were considered those with Benjamini-Hochberg false discovery rate 
FDR q-value < 0.1. 
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Immunofluorescence of Adult Mouse Lung Sections 
Adult mouse lungs were inflated and fixed in cold 4% paraformaldehyde in PBS 
overnight at 4°C. Following fixation, cells were embedded in Tissue-Tek® O.C.T. 
(optimal cutting temperature) compound for cryo-sectioning or in paraffin wax for 
paraffin sectioning. For imaging of Acta2hrGFP and Cspg4DsRed reporter expression 
in the adult mouse lung, frozen sections of adult mouse lungs were mounted 
using Prolong Diamond Anti-Fade Mounting Reagent with DAPI (ThermoFisher). 
For immunofluorescence, paraffin lung sections were blocked with 5% normal 
donkey serum (Sigma) for 1 hour at room temperature. Sections were incubated 
with primary antibodies against Acta2 (ThermoFisher) and Hhip (Sigma) 
overnight at 4°C, washed, and then incubated with secondary antibodies for 1 
hour at room temperature. After antibody staining, lung sections were 
coverslipped using Prolong Diamond Anti-Fade Mounting Reagent with DAPI. All 
lung sections were imaged using a Nikon (Tokyo, Japan) deconvolution 
microscope. 
 
5.3 Results 
Identifying Gene Signatures of Primary Adult Mouse Lung Vascular Smooth 
Muscle and Airway Smooth Muscle 
To begin to address the question of differences between smooth muscle cell 
subtypes, we utilized a double-transgenic fluorescent reporter mouse with a 
humanized Renilla reniformis green fluorescent protein (hrGFP) following a rat 
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Acta2 promoter sequence (Acta2hrGFP) and a red fluorescent protein (DsRed) 
under the control of a mouse Cspg4 promoter (Cspg4DsRed)105. In the adult mouse 
lung, the Acta2hrGFP exclusively marks smooth muscle cell populations, with the 
Cspg4DsRed expression distinguishing between vascular smooth muscle cells 
(Acta2hrGFP+ / Cspg4DsRed+) and airway smooth muscle cells (Acta2hrGFP+ / 
Cspg4DsRed-) (Figure 5.1). Adult mouse lungs between 3 to 6 months of age were 
enzymatically digested and flow sorted to isolate the vSMC and aSMC 
populations (Figure 5.2A), and we performed microarray analysis on the two 
populations to begin to identify distinct gene signatures of SMC subtypes. 
Principal component analysis (PCA) revealed that the vSMC and aSMC 
populations clustered distinctly from each other along the PC2 axis, which 
accounts for 11% of the variance (Figure 5.2B). To identify unique gene 
signatures for the vSMC and aSMC populations, a moderated t-test was 
performed for each gene between the two populations. We identified unique 
gene signatures for the vSMC and aSMC populations, which was defined as the 
top 50 differentially expressed genes for either population using an FDR q-value 
<0.05 (Figure 5.3). Acta2 is not differentially expressed between the vSMC and 
aSMC populations, and Cspg4 is differentially expressed with enrichment in the 
vSMC population. 
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Figure 5.1: Immunofluorescence image of a frozen section of adult mouse lung 
from a double-transgenic Acta2hrGFP Cspg4DsRed reporter mouse. Images show 
the expression of the Acta2hrGFP (green) and Cspg  4DsRed (red) reporters co-
stained with DAPI for nuclei (blue).  
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Figure 5.2: Microarray analysis of adult mouse lung vascular SMCs and airway 
SMCs. A) Schematic showing experimental set-up of microarray profiling of 
vSMCs and aSMCs from the adult mouse lung of an Acta2hrGFP Cspg4DsRed 
mouse. Vascular smooth muscle cells (Acta2hrGFP+ / Cspg4DsRed+), airway smooth 
muscle cells (Acta2hrGFP+ / Cspg4DsRed-), and pericytes (Acta2hrGFP- / Cspg4DsRed+) 
can be identified using flow cytometry. B) Principal component analysis (PCA) 
plot showing clustering of vSMCs, aSMCs and undifferentiated miPSCs.  
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Figure 5.3: Microarray gene signature of adult mouse lung vascular SMCs and 
airway SMCs. Heat maps show the top 50 differentially expressed genes 
between vSMCs (left) and aSMCs (right) with an FDR filtered q-value < 0.05. 
Heat maps are row normalized. 
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Comparison of Microarray Profile of vSMCs and aSMCs to Single Cell RNA-
Sequencing Database of Adult Mouse Lung Mesenchymal Populations 
Recently, Zepp et al. from the Morissey group at the University of Pennsylvania 
published a single cell RNA-sequencing data set of adult mouse lung 
mesenchymal populations171. We were interested in comparing our data sets and 
observing where the vSMC and aSMC populations are within their data set. We 
visualized the Zepp et al. data set using the SPRING software172 (Figure 5.4A), 
and we overlaid our vSMC and aSMC gene signatures (Figure 5.4B and C). 
These vSMC and aSMC gene sets were mostly expressed in two distinct clusters 
found within the Zepp et al. data set. Both clusters expressed Acta2 (Figure 
5.4D), with the vSMC cluster expressing higher levels of Acta2 compared to the 
aSMC cluster. These two clusters also show distinct expression levels of the 
genes identified in the vSMC and aSMC microarray gene signature.  Timp4, 
tissue inhibitor of metalloproteinases, (Figure 5.4E) was distinctly expressed in 
the vSMC cluster, and Hhip, hedgehog interacting protein (Figure 5.4F), was 
distinctly expressed in the aSMC cluster in the SPRING visualization. To better 
understand expression profiles of the clusters with identified vSMC and aSMC 
clusters in the Zepp et al. data set, we first used the “Show enriched genes” tool 
within the SPRING web-tool to generate a list of the enriched genes in each 
population. We also used a graph based clustering algorithm (Seurat R package) 
to identify clusters within the Zepp et al. data set. The vSMC and aSMC clusters 
identified from the SPRING software were then compared to each other to 
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identify differentially expressed genes between those clusters (Table 5.1). 
Comparing the differentially expressed genes for the vSMC and aSMC clusters 
generated from our microarray analysis, the SPRING software, and the DESeq2 
package in the R environment, we identified a list of overlapping genes that 
identify each SMC subtype. To validate some of these genes as markers of 
either vSMC or aSMC subtype, we performed immunofluorescent staining on 
adult mouse lung sections. Hhip was co-expressed with Acta2 in the airway 
smooth muscle but had minimal to no expression in the vascular smooth muscle, 
which were Acta2+ (Figure 5.5A and 5.5B). In addition, we observed a Hhip+ 
Acta2- population surrounding a thin Acta2+ Hhip- population in the veins. Since 
Hhip is involved in the hedgehog signaling pathway, we looked at expression 
levels of other known hedgehog signaling pathway genes in our microarray data 
set and the Zepp et al. data set. Ptch1, Gli1, and Gli3 were not very highly 
expressed in our microarray (data not shown) or in the Zepp et al. data set in any 
of the mesenchymal populations (Figure 5.4D, 5.4E, and 5.4F). 
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Figure 5.4: SPRING visualization of single cell RNA-sequencing data of adult 
mouse lung mesenchymal populations from Zepp et al. (2017). A) SPRING plot 
of adult mouse lung mesenchymal populations. B and C) Expression of vSMC 
and aSMC gene sets, respectively, using the gene signature from Figure 5.3. 
Expression of D) Acta2, E) Timp4, F) Hhip, G) Ptch1, H) Gli1, and I) Gli3 genes 
in the lung mesenchymal populations.  
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Table 5.1: Table of the top 20 differentially expressed genes between the vSMC 
and aSMC clusters identified in the Zepp et al. data set.  
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Figure 5.5: Immunofluorescence imaging of adult mouse lung sections stained 
for DAPI (blue), Hhip (green), and Acta2 (red). Images were taken from A) 
proximal and B) distal lung sections. a – airway, v – vascular.  
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Identification of Primary SMC Subtype Gene Signatures Using Microarray 
Profiling of Adult Mouse Lung Vascular SMC, Airway SMC, and Aortic SMC 
We wanted to try to identify further SMC subtype-specific gene signatures, so we 
performed a combined analysis of the microarray profiling of lung vSMCs and 
aSMCs with the microarray profiling of aortic SMCs (aoSMCs) from Chapter 2 
(Figure 5.6A). Principal component analysis (PCA) showed minimal batch effects 
from combining this data as shown by the clustering of undifferentiated miPSCs 
profiled in both microarray runs (Figure 5.6B). The different SMC subtypes also 
clustered separately along the PC2 axis, which accounted for 12% of the 
variance. Using an FDR q-value <0.05 for t-test comparisons, we generated gene 
signatures for lung vSMCs, aSMCs, and aoSMCs (Figure 5.6C), where genes 
were highly expressed in one SMC subtype relative to the other two SMC 
subtypes (fold change >|5|). A general vSMC gene signature was also found 
where genes were highly expressed and overlapped in both lung vSMCs and 
aoSMCs compared to aSMCs. The lung vascular SMC gene signature based off 
of this comparison of microarray profiling included 3 genes: Odf3l1, Gabrq, and 
B3gnt5. The airway SMC gene signature included Hhip and Lgr5191, which has 
been previously described as a marker of distal lung mesenchyme. Comparing 
the iPSC-derived Acta2hrGFP+ cells to the primary SMCs, we saw that the in vitro 
derived Acta2hrGFP+ population clusters closest to aortic SMCs and lung vascular 
SMCs, although the in vitro population still remains far away from the primary 
SMCs, which are all clustered fairly close together. 
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Figure 5.6: Microarray gene signatures of adult mouse aortic SMC, lung vascular 
SMC, and airway SMC. A) Schematic showing microarray profiling experimental 
set-up. B) Principal component analysis (PCA) plot of the aortic SMC, vascular 
SMCs, airway SMCs, and undifferentiated miPSCs from each experiment. C) 
Heat maps showing the distinct gene signatures of each SMC subtype. Heat 
maps are row normalized. D) PCA plot of iPSC-derived Acta2hrGFP+ cells with 
primary SMCs. 
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Generation of Acta2hrGFP Cspg4DsRed Mouse iPSC Reporter System for 
Isolation of SMC Subtypes 
After identifying distinct molecular gene signatures of smooth muscle cell 
subtypes, we were interested in developing a reporter system for isolating more 
specific SMC subtypes. Tail tip fibroblasts from Acta2hrGFP Cspg4DsRed mice were 
harvested and reprogrammed into mouse induced pluripotent stem cells (Figure 
5.7A) using methods as described previously in Chapter 2. Acta2hrGFP Cspg4DsRed 
miPSCs were stained for pluripotency markers, and pre-excised lines were 
karyotypically normal (Figure 5.7B). We differentiated the Acta2hrGFP Cspg4DsRed 
miPSC line towards Acta2hrGFP+ cells using the directed differentiation protocol to 
smooth muscle-like cells established in Chapter 2 (Figure 5.7C). By day 13, we 
observed Acta2hrGFP+ Cspg4DsRed- cells as seen previously using the Acta2hrGFP 
miPSC line. By extending the directed differentiation protocol further, we begin to 
see expression of Acta2hrGFP+ Cspg4Dsred+ cells in addition to the Acta2hrGFP+ 
Cspg4DsRed- population by day 16 and day 22 (Figure 5.7D). Comparing sorted 
populations on day 22, we saw that both the Acta2hrGFP+ populations were 
enriched for Acta2 by gene expression (Figure 5.7E). Cspg4DsRed+ populations 
were also enriched for expression of Cspg4. The Acta2hrGFP+ Cspg4Dsred- and 
Acta2hrGFP+ Cspg4Dsred+ populations were also enriched for characteristic smooth 
muscle markers, Tagln and Myh11.  To identify pathways that might pattern or 
specify SMCs towards a specific subtype, we performed GSEA analysis to find 
gene sets that were enriched in either vSMCs (Table 5.2) or aSMCs (Table 5.3). 
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The “MTORC1 signaling” gene set is enriched in vSMCs, and “Hedgehog 
signaling”, “TNFA Signaling via NFKB”, “IL6 JAK STAT3 Signaling”, and “IL2 
STAT5 Signaling” gene sets are enriched in aSMCs. Although “Wnt Beta Catenin 
Signaling”, “Notch Signaling”, and “TGF-Beta Signaling” gene sets are not 
significantly enriched in either SMC population based on GSEA analysis, Hey2, 
Id2, Wnt5a were some of the top differentially expressed transcription factors in 
either vSMCs or aSMCs (Figure 5.8). 
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Figure 5.7: Generation and directed differentiation of Acta2hrGFP Cspg4DsRed 
mouse iPSC reporter line. A) Schematic of Acta2hrGFP Cspg4DsRed miPSC line 
generation and differentiation. B) Pluripotency markers in miPSCs and karyotype 
of miPSCs. C) Directed differentiation protocol towards SMC-like lineage. D) 
Flow cytometry plots showing kinetic of reporter expression from Day 13 to Day 
22 of directed differentiation. E) Gene expression of sorted populations from Day 
22 of directed differentiation for Acta2, Cspg4, Tagln, Myh11. 
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Table 5.2: GSEA analysis showing enriched gene sets in the vSMC population. 
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Table 5.3: GSEA analysis showing enriched gene sets in the aSMC population. 
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Figure 5.8: Heat maps of top 25 differentially expressed (FDR q-value <0.05) 
transcription factors with enriched expression in vSMCs (left) and aSMCs (right).  
 
5.4 Discussion and Future Directions 
Our results identified unique gene signatures for adult mouse primary smooth 
muscle cell subtypes. Previously, literature had described splice variants of Smtn 
as a way to differentiate between visceral and vascular SMCs or defined 
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transcriptomic profiles after propagation of SMCs in culture. Using microarray 
profiling of fresh primary adult mouse lung vascular SMC and airway SMC, we 
identified gene signatures of the top 50 differentially expressed genes in each 
population. In our study, we identified Hhip as a novel marker of airway SMCs. 
Hhip, or hedgehog interacting protein, is involved in the hedgehog signaling 
pathway which has been described in the interactions between lung epithelium 
and mesenchyme during lung development.  Additionally, Hhip has been linked 
to chronic obstructive pulmonary disorder through genome wide association 
studies (GWAS). We also performed a combined analysis with microarray 
profiling of aortic SMCs to further define gene signatures of SMC subtypes. 
Future work will use this microarray profiling to further identify and validate 
markers for each SMC subtype. Due to most characteristic markers of SMCs 
being intracellular, we developed reporter systems to isolate populations of 
smooth muscle-like cells from our directed differentiations in vitro. The 
identification of novel cell surface markers from the described gene signatures 
will allow for purification of SMC subtypes both in vivo and in in vitro directed 
differentiation of mouse iPSCs without gene editing to introduce reporters.  
 
In addition to characterizing in vivo gene signatures of smooth muscle cell 
subtypes, we described the generation of a Acta2hrGFP Cspg4Dsred mouse reporter 
iPSC line, which was differentiated towards smooth muscle-like lineages that 
were either Acta2hrGFP+ Cspg4Dsred+ or Acta2hrGFP+ Cspg4Dsred-. These populations 
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were also enriched for characteristic SMC markers in terms of gene expression. 
This finding extends on the work previously shown in Chapter 2 of using a 
reporter iPSC line to isolate populations of Acta2hrGFP+ cells enriched for SMC 
markers. Future work will use this line to better characterize the different 
populations derived using the differentiation protocol for smooth muscle-like cells 
and the identified gene signatures of SMC subtypes. Furthermore, the pathways 
identified from GSEA analysis and from the differentially expressed transcription 
factors will be used with this line to try to understand the role of these pathways 
in specifying SMC subtypes in vitro.  
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CHAPTER 6: GENERAL DISCUSSION AND FUTURE DIRECTIONS 
In this dissertation, we generated mouse and human iPSC reporter systems for 
tracking and isolating populations of Acta2hrGFP+ or ACTA2eGFP+ smooth muscle-
like cells and utilized an enzymatically degradable hydrogel system to generate 
iPSC-derived smooth muscle-like cells sheets. In addition, we profiled and 
identified gene signatures of primary adult SMC subtypes (lung vascular SMCs, 
airway SMCs, and aortic SMCs), where we identified Hhip as a novel marker of 
airway SMCs in the adult mouse lung. 
 
Despite these advances, many questions still remain. One major question that 
still remains is how we define a smooth muscle cell. As discussed in Chapter 1, 
smooth muscle cells can “differentiate” or “de-differentiate” between a contractile 
phenotype and a synthetic phenotype56,57. Even in the in vivo system, smooth 
muscle cells can display a phenotype along this spectrum of synthetic and 
contractile phenotypes. Furthermore, many of the characteristic smooth muscle 
cell markers are not specific to smooth muscle cells, making it difficult to use 
solely gene expression to identify smooth muscle cell populations. Many of the 
SMC markers are also expressed in cardiomyocytes as well as 
myofibroblasts56,57. In addition, these markers are also expressed at different 
times and at different expression levels during development. The combination of 
these issues makes it difficult to identify a smooth muscle cell through the 
expression of a gene or even a panel of non-specific genes. Since one of the 
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main functions of SMCs is to contract, functional studies of smooth muscle cells 
involve contraction assays and calcium flux imaging; however, myofibroblasts 
have also been shown to generate forces. The identification of distinct 
characteristic markers and functional assays will be crucial in determining the 
identity of iPSC-derived smooth muscle cells.  
 
Furthermore, the panel of characteristic smooth muscle cell marker genes does 
not distinguish between different smooth muscle cell subtypes. As described in 
Chapter 1, the heterogeneity of embryological origins of smooth muscle cells and 
the implications in diseases have begun to be explored95-98. Some markers, such 
as Notch3, Cspg4, and Smtn105,106, have been discussed as markers that can 
distinguish between vascular and visceral smooth muscle cells. However, there 
still remains a lack of global transcriptomic gene signatures of different smooth 
muscle cell types to help in the characterization of iPSC-derived smooth muscle 
cells. The identification of novel gene signatures of smooth muscle cell subtypes 
in Chapter 5 provides a roadmap to identify 1) what smooth muscle subtype is 
being derived in iPSC directed differentiation protocols and 2) pathways that 
pattern or specify smooth muscle cells towards a certain smooth muscle subtype. 
Comparing the global transcriptomic profile of our iPSC-derived Acta2hrGFP+ cells 
with that of primary SMCs showed that our cells cluster more closely to vascular 
smooth muscle cells, but the in vitro cells still cluster far away from the primary 
SMCs, which all cluster separately but in close proximity to each other. The gene 
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signature of our in vitro cells was reminiscent of an immature or synthetic SMC 
phenotype, and we have identified the Notch pathway as a possible pathway to 
modulate to induce our cells to a more contractile phenotype. Other strategies 
such as biomechanical cues, mechanical condition, and biochemical factors can 
also be tested to differentiate our cells into a more contractile and mature SMC 
phenotype. We have also identified a few pathways, including Hedgehog and 
Wnt, as possible pathways to pattern or specify our in vitro iPSC-derived cells to 
a more airway SMC or vascular SMC phenotype. Furthermore, we have yet to 
identify and validate cell surface markers of the different SMC subtypes using our 
microarray profiling. The identification of novel and unique cell surface markers 
will allow for the use of iPSC systems without reporters as well as being able to 
identify SMC subtypes using a distinct panel of markers. 
 
We have also identified Hhip as a novel marker of airway smooth muscle cells 
using our global profiling of primary SMC subtypes. This finding was validated 
against the data set single cell RNA sequencing study of adult lung 
mesenchymal populations. In addition, we have stained for Hhip and Acta2 co-
expression in adult mouse lung sections.  Hhip has been implicated in both 
asthma and chronic obstructive pulmonary disease (COPD) through genome 
wide association studies (GWAS)205,206. Through our global transcriptome 
profiling, other Hedghog pathway signaling genes are lowly expressed in airway 
smooth muscle cells, so further studies to understand the role of Hhip in aSMCs 
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will need to be performed. 
 
Another area of interest that remains is the tissue engineering and regenerative 
medicine aspect, including further developing a blood vessel replacement as well 
as developing in vitro model systems for studying interactions between cells. We 
have shown preliminary work using the iPSC-derived Acta2hrGFP+ population to 
generate cell sheets, which can function as a building block to the development 
of a multi-layered blood vessel replacement; however many questions still 
remain, including the use of the hiPSC-derived ACTA2eGFP+ population as well as 
the process to go from a layered stack of aligned cell sheets to a tubular blood 
vessel graft. Further mechanical characterization and ECM quantification is also 
required to characterize the cell-sheet engineered constructs efficacy. Besides 
further developing the blood vessel replacement, the iPSC-derived cells and cell 
sheet engineering techniques can be utilized to study different cell layer 
interactions. As discussed above, if iPSC-derived SMCs can be patterned 
towards an airway SMC, lung vascular SMC, or an aortic SMC, we can generate 
vascular SMC cell sheets that can be stacked with endothelial cell sheets to 
study the interactions of endothelial cells and smooth muscle cells. Moreover, 
iPSC-derived airway SMCs would allow for development of iPSC-based models 
to study proximal lung epithelial cells in organoid or ALI culture systems192,193.  
 
Finally, with the development of a reporter human iPSC system to derive smooth 
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muscle cells, we can begin to develop models to study hereditary pulmonary 
arterial hypertension (HPAH). Many studies have been trying to elucidate the 
roles of endothelial cells and smooth muscle cells in pulmonary hypertension. In 
addition, current animal models do not properly recapitulate the disease 
pathology, so there is a need for other model systems to study the etiology of the 
disease. Mutations in the BMPR2 locus have been linked with hereditary 
pulmonary arterial hypertension, making induced pluripotent stem cells a 
promising model system to study HPAH186-188. A couple studies differentiating 
iPSCs towards an endothelial-like lineage have started addressing pathways that 
might be involved in HPAH179,180; however, it is unclear how similar the iPSC-
derived endothelial-like cells are to pulmonary arterial endothelial cells. By using 
the BMPR2 patient-specific lines that we have knocked-in an ACTA2eGFP reporter 
into, we can isolate pure populations of smooth muscle-like cells to study the role 
of SMCs in HPAH. Furthermore, the identification of novel gene signatures of 
primary smooth muscle cells, specifically lung vascular smooth muscle cells, will 
provide a roadmap for characterizing how close our iPSC-derived ACTA2eGFP+ 
cells are to pulmonary arterial smooth muscle cells as well as provide some 
insight into pathways for patterning the ACTA2eGFP+ population during the 
directed differentiation. Lastly, using the same BMPR2 patient specific lines, we 
can also derive endothelial-like cells, which can be used to interrogate the 
interactions between endothelial cells and smooth muscle cells in the 
pathophysiology of hereditary pulmonary arterial hypertension.  
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